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ABSTRACT 
Little is known about the bidirectional interaction between the bile acid (BA) sensor farnesoid 
X receptor (FXR) and microRNAs (miRNAs) in diseases of the human digestive system. The 
nuclear receptor FXR has been shown to play a key role in the regulation of metabolic 
pathways, inflammatory response and cell cycle regulation in liver and intestine. MiRNAs are 
currently gaining interest as potential drug targets, because they regulate the expression of 
approximately 60% of all human genes and they appear to be at the center of the balance 
between cell proliferation and apoptosis. Thus, miRNA molecules are currently entering the 
clinical test phase as putative future treatment options for several diseases of the human 
digestive system such as steatohepatitis, cholestasis, (cholangio)hepatocellular carcinoma or 
colon cancer. The ability of miRNAs to simultaneously influence the expression of a large set 
of genes is controversially discussed in the literature. This “one-to-multiple” relationship of 
miRNAs can be beneficial in multipathway diseases such as cancer, where several oncogenes 
can be miRNA-dependently suppressed. In contrast, the risk for drug-associated undesired 
off-target effects is increased by targeting a miRNA as compared to influencing the target 
gene itself. Here we elucidate how miRNAs are involved in the regulation of FXR expression 
and influence the physiological and pathophysiological role of FXR. Based on the results, we 
further discuss miRNAs as potential drug targets and therapeutic agents for liver and digestive 
diseases. 
This thesis consists of three parts. In the first part, we show that strongest activation of the 
BA-FXR axis significantly influences the expression of 81 miRNAs and 2304 genes, all of 
which are known to be involved in hepatic lipid, BA and drug metabolism. Further, the p53-
regulated, apoptotic miRNA miR-34a is BA-dependently suppressed and shows an inverse 
expression correlation with several genes important for the maintenance of BA homeostasis. 
Based on this finding we suggest that miR-34a plays a key role in the autoregulation of BA 
homeostasis, conferring a link between BA dysregulation and apoptosis in dependence of 
FXR transactivation. In the second part, we demonstrate that FXR itself is epigenetically 
regulated by miR-192 in hepatoma and colon cancer-derived cell lines. MiR-192 is, like miR-
34a, a p53-regulated miRNA known to be important in cell proliferative and apoptotic 
processes. We further show that also miR-192 has the potential to influence BA homeostasis 
by FXR-dependent suppression of the expression of relevant BA transporters such as BSEP, 
MRP2 and OSTα/β. Additionally, miR-192-3p transfection results in a partially FXR-
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dependent, decreased proliferation of Huh-7 cells, whereas miR-192 also shows some FXR-
independent effects on cell viability and cell cycle regulatory pathways. In the last part of this 
thesis, we focus on the miRNA-dependent regulation of the FXR-controlled drug transporter 
OATP1B3. We reveal that OATP1B3 expression is directly regulated by three miRNAs, miR-
509-5p/-3p and miR-656, whereas miR-192-5p and -3p also suppress OATP1B3 expression in 
a FXR-dependent manner. By this “multi-to-one” relationship of miRNA-dependent 
regulation of OATP1B3 expression, the complexity of the endogenous miRNA-dependent 
gene regulatory network is discussed. 
In summary, we demonstrate that a bidirectional interaction between the bile acid sensor FXR 
and miRNAs is of importance for physiological and pathological effects on the human 
digestive system. The complexity of the endogenous miRNA network may have important 
consequences for the development of miRNA therapeutics. With focus on the p53-regulated 
miRNAs miR-34a and miR-192, we discuss current problems in miRNA therapeutic 
development such as tissue specificity and undesired off-target effects. As the reproducibility 
of in vitro miRNA studies is low, early performance of human studies is inevitable. We 
conclude that miRNAs such as miR-192 or miR-34a are high-value drug targets and agents, 
when targeted drug delivery to the diseased tissue can be achieved. A drug distribution of 
mimics into healthy tissue should be avoided for both p53-regulated miRNAs, as they have 
the potential to disturb the BA-FXR axis and may decrease cell viability. Since not all 
mechanisms of miRNA-dependent gene regulation are probably discovered yet, continuous 
miRNA research is still essential for the development of truly innovative and safe treatment 
concepts. 
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ZUSAMMENFASSUNG 
Über die bidirektionale Interaktion zwischen dem Gallensäure-Sensor Farnesoid-X Rezeptor 
(FXR) und microRNAs (miRNAs) bei Erkrankungen des menschlichen Verdauungsapparates 
ist nur wenig bekannt. Der Kernrezeptor FXR spielt eine Schlüsselrolle in der metabolischen 
Regulation, der Entzündungsantwort sowie in der Zellzyklen-Kontrolle in Leber und Darm. 
MiRNAs gewinnen als therapeutische Ansatzpunkte immer mehr an Bedeutung, da sie bis zu 
60% der menschlichen Gene zu regulieren scheinen und eine zentrale Rolle im Gleichgewicht 
zwischen Zellwachstum und Apoptose einnehmen. Einzelne miRNA-Moleküle werden in 
klinischen Studien schon als therapeutische Arzneimittel gegen Erkrankungen wie 
Steatohepatitis, Cholestase, (cholangio)-hepatozelluläres Karzinom oder auch Kolonkarzinom 
getestet. Die Fähigkeit von miRNAs, zeitgleich die Expression von mehreren Genen 
regulieren zu können, wird in der Fachliteratur kontrovers diskutiert. Diese Fähigkeit kann 
zum Beispiel bei Krebserkrankungen, bei welchen meist mehrere Onkogene und 
entsprechende Signalwege dysreguliert sind, von Vorteil sein. Zum anderen besteht bei 
miRNA-basierten Therapeutika immer das unerwünschte Risiko für „off-target“ Effekte – 
wahrscheinlich mit einem höheren Risiko, als wenn man das Zielprotein selbst medikamentös 
beeinflussen würde. In dieser Dissertation wird veranschaulicht, wie miRNAs in der 
Expressionsregulierung von FXR und an dessen physiologischer und pathophysiologischer 
Wirkung beteiligt sind. Weiter wird auf Vor- und Nachteile von möglichen miRNA-
Therapeutika bei Leber- und Darmerkrankungen eingegangen.  
Diese schriftliche Arbeit besteht aus drei Teilen. Im ersten Kapitel wird veranschaulicht, dass 
die Expression von 81 miRNAs und 2304 Genen, welche im hepatischen Lipid-, 
Gallensäuren- und Medikamentenmetabolismus involviert sind, durch Aktivierung der 
Gallensäure/FXR-Achse signifikant beeinflusst wird. Die p53-regulierte, apoptotische 
miRNA miR-34a wird Gallensäure-abhängig supprimiert und zeigt eine inverse 
Expressionskorrelation mit mehreren Genen, welche für die Aufrechterhaltung der endogenen 
Gallensäurehomöostase wichtig sind. Anhand dieser Resultate können wir schlussfolgern, 
dass miR-34a eine potentielle Schlüsselrolle in der Autoregulation der 
Gallensäurehomöostase spielt. Weiter zeigt uns dieses Beispiel einen Zusammenhang 
zwischen Gallensäuredysregulation und Apoptosis in Abhängigkeit der Transaktivierung von 
FXR. Im zweiten Teil zeigen wir in Hepatom- und Kolonkarzinom-Zelllinien, dass die 
Expression von FXR durch miR-192 epigenetisch kontrolliert wird. MiR-192 gehört wie miR-
34a zu den p53-gesteuerten miRNAs, welche für ihre Wichtigkeit in 
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zellproliferativen und apoptotischen Prozessen bekannt sind. Wir heben zudem hervor, dass 
auch miR-192 die Gallensäurehomöostase durch eine FXR-abhängige Suppression der 
Expression von relevanten Gallensäuretransportern (u.a. BSEP, MRP2 und OSTα/β) 
potentiell negativ beeinflussen kann. Die Transfektion von miR-192-3p resultiert weiter in 
einem verminderten Wachstum von Huh-7 Zellen, wobei dieser miR-192-Effekt zu einem 
gewissen Anteil als FXR-abhängig interpretiert werden kann. MiR-192 zeigt jedoch auch 
FXR-unabhängige Effekte, z.B. auf die Zelllebensfähigkeit sowie auf Zellzyklus-
regulatorische Signalwege von Huh-7 Zellen. Der letzte Teil dieser Dissertation fokussiert auf 
die miRNA-abhängige Regulation des FXR-kontrollierten Medikamententransporters 
OATP1B3. Wir zeigen, dass die Expression von OATP1B3 durch drei miRNAs direkt 
reguliert wird (miR-509-5p/-3p und miR-656) sowie, dass miR-192-5p und -3p indirekt, 
durch ihren Einfluss auf FXR, die OATP1B3 Expression herunterregulieren. Anhand dieses 
Beispiels, welches aufzeigt, dass die Expression von einem Gen von mehreren miRNAs 
gleichzeitig reguliert werden kann, diskutieren wir die Komplexität des endogenen miRNA-
Netzwerks. 
Zusammenfassend können wir mit dieser Arbeit hervorheben, dass eine bidirektionale 
Interaktion zwischen dem Gallensäure-Sensor FXR und miRNAs eine entscheidende Rolle in 
der Physiologie und Pathophysiologie des humanen Verdauungssystems einnimmt. Die 
veranschaulichte Komplexität des endogenen miRNA-Netzwerks könnte klinisch relevante 
Probleme während der Entwicklung von miRNA-Therapeutika hervorrufen. Mit Bezug auf 
die p53-regulierten miRNAs miR-34a und miR-192 veranschaulichen wir aktuelle Probleme 
in der miRNA-basierten Medikamentenentwicklung wie z.B. Zielstrukturspezifität sowie 
unerwünschte „off-target“ Effekte. Die Reproduzierbarkeit von miRNA-assoziierten in vitro 
Studien ist grundsätzlich sehr niedrig, womit eine zeitnahe Durchführung von Humanstudien 
unumgänglich ist. Wir können somit schlussfolgern, dass miRNAs wie miR-192 oder miR-
34a hochwertige therapeutische Ansatzpunkte sind, falls eine zielgerichtete 
Medikamentenverteilung in erkranktes Gewebe möglich ist. Eine Verteilung in gesundes 
Gewebe sollte im Falle von p53-regulierten miRNA-Molekülen sicherlich vermieden werden, 
da die Gallensäure/FXR-Achse potentiell dysreguliert sowie die Lebensfähigkeit von 
gesunden Zellen vermindert werden kann. Da bis heute wahrscheinlich noch nicht alle 
Mechanismen der miRNA-abhängigen Genregulation bekannt sind, ist eine weiterführende 
miRNA Forschung für die zukünftige Entwicklung von innovativen und gut tolerierbaren 
miRNA-Therapeutika unabdingbar.  
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ABBREVIATIONS 
 
ABC – ATP-binding cassette 
ACAT1 – acetyl-CoA acetyltransferase 1 gene 
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DME – drug metabolism enzymes 
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FABP – fatty acid-binding protein 
FASN – fatty acid synthase gene 
FDR – false discovery rate 
FGF19 – fibroblast growth factor 19 
FGFR4 – fibroblast growth factor receptor 4 
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GLP-1 – glucagon-like peptide 1 
HBV – hepatitis B virus 
HCC – hepatocellular carcinoma 
HCV – hepatitis C virus 
HDL – high density lipoprotein 
HMGCS2 – 3-hydroxy-3-methylglutaryl-CoA 
synthase 2 
HNF – hepatocyte nuclear factor 
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ICC – intrahepatic cholangiocarcinoma 
IL – interleukin 
JNK – c-jun n-terminal kinase 
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ix | ABBREVIATIONS 
 
 
 
MDR3 – multidrug resistance protein 3  
miRNA/miR – microRNA 
mRNA – messenger RNA 
MRP2 – multidrug resistance-associated 
protein 2 
NAFLD – non-alcoholic fatty liver disease 
NASH – non-alcoholic steatohepatitis 
NC – negative control 
NFκB – nuclear factor κ-light-chain-enhancer 
of activated B cells 
NGS – next generation sequencing 
NOS – nitric oxide synthase 
NPC1L1 – Niemann-Pick C1-like 1 gene 
NTCP – Na+-taurocholate cotransporting 
polypeptide. 
OATP – organic anion transporting 
polypeptide 
OCA – obeticholic acid 
OST – organic solute transporter 
PCR – polymerase chain reaction 
PCSK9 – proprotein convertase subtilisin/ 
kexin type 9 
PFIC – progressive familial intrahepatic 
cholestasis 
PGC – peroxisome proliferator-activated 
receptor gamma coactivator 
PHH – primary human hepatocytes 
PPAR – peroxisome proliferator-activated 
receptor 
PRKCA – protein kinase C alpha 
PXR – pregnane X receptor 
RAR – retinoic acid receptor 
RISC – RNA-induced silencing complex 
RNA – ribonucleic acid 
ROS – reactive oxygen species 
RT-PCR – real-time polymerase chain reaction 
RXR – retinoid X receptor 
S1PR – sphingosine-1-phosphate receptor 
SDS – sodium dodecyl sulfate 
SHP – small heterodimer partner 
SIP1 – smad interacting protein 1 
siRNA – small interfering RNA 
SIRT1 – sirtuin-1 
SLC – solute carrier family 
SREBF2 – sterol regulatory element binding 
transcription factor 2 
SREBP-1c – steroid response element binding 
protein 1c  
STARD3 – StAR-related lipid transfer domain 
protein 3 
SULT – sulfotransferase 
TCA – taurocholic acid 
TGF – transforming growth factor 
TNF – tumor necrosis factor 
TSS – transcription start site 
UDCA – ursodeoxycholic acid 
UGT – UDP-glucuronosyltransferase 
UTR – untranslated region 
VEGFA – vascular endothelial growth factor A 
VLDL – very low density lipoprotein 
ZEB2 – zinc finger E-box binding homeobox 2 
 
 
 
 
    1 | INTRODUCTION 
 
I. INTRODUCTION 
1. Physiology of the human digestive system 
The human digestive system consists of the gastrointestinal tract, the liver, the pancreas, and 
the gallbladder. The digestive system helps the body to break down food into nutrients 
(carbohydrates, proteins, fat, and vitamins), which are used for energy, growth, and cell 
repair. Digestion requires the interplay between organs, hormones, and nerves involving the 
whole human body as such. The hormone cholecystokinin (CCK) for example, is a key 
regulator of food ingestion and digestion. During meal intake, it is secreted from the small 
intestine, where it facilitates the secretion of pancreatic enzymes and bile from the gallbladder 
[1]. Bile acids (BA), one of the main constituents of the bile, are potent digestive surfactants 
that promote the absorption of lipids and fat-soluble vitamins from the intestine into the 
circulatory system.  
Orally taken drugs can enter the human body over the digestive system. For most of them, 
their bioavailability is dependent on transporters or metabolizing enzymes located in the liver 
or intestine. Many drugs are known to influence the activity of drug transporters or enzymes 
affecting the pharmacokinetics of other therapeutics, thus leading to drug-drug interactions. 
Some of these transporters and enzymes are as well important for the maintenance of BA 
homeostasis.  
 
1.1 The liver 
The liver is the largest organ of the human organism, constituting approximately 2-3% of 
average body weight. Being strongly vascularized, it receives up to 25% of the total cardiac 
output. The liver consists of four lobules and has a dual blood supply: the hepatic artery and 
the portal vein [2]. The classical structural unit of the liver is the hepatic lobule, having a 
shape of a polygon. The lobule is composed of the central vein in the center and the portal 
triad at the corners, consisting of the hepatic artery, the portal vein and the bile duct. Plates of 
hepatocytes radiate from the central vein to the perimeter of the lobule to define the hepatic 
acinus, the functional unit of the liver. The hepatic acinus is divided into three zones, 
categorizing the hepatocyte strains regarding their functional activity (Fig. 1) [3]. Nearly 80% 
of the total liver volume is constituted by hepatocytes. Other liver cells encompass 
cholangiocytes as epithelial cells of the intrahepatic bile ducts, liver sinusoidal endothelial 
cells, hepatic stellate cells, Kupffer cells and pit cells such as intrahepatic lymphocytes or 
natural killer cells [4].  
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Figure 1: Three-dimensional architecture of the liver between the central vein and a portal triad (A), and 
functional zones of the hepatic acinus (B). The networks of bile canaliculi (yellow-green) run parallel and 
counter to the blood flow through the sinusoids. Adapted from [3]. 
 
 
The main liver functions are metabolic regulation, hematological regulation (e.g. production 
of coagulation proteins), and bile production. The liver is the most important detoxifying 
organ in human body, which metabolizes endogenous molecules and xenobiotics, and 
contributes to the clearance of drugs and toxins over the urine or feces. The liver is 
furthermore important for storage of nutrients such as glucose, fat-soluble vitamins or iron 
[5]. 
 
1.2 The intestine 
The small intestine and colon (large intestine) are essential parts of the gut, whose main 
function is nutrient digestion and absorption as well as feces formation. The small intestine is 
structurally divided into duodenum, jejunum and ileum. To increase resorption ability, the 
small intestine contains crypts and villi leading to an intestinal surface enlargement. A tight 
capillary network, directly located under the epithelium, is important for a rapid resorption of 
nutrients and drugs [6]. The colon can be divided into four sections and its main task is the 
removal of water, salt and nutrients from the chyme for feces formation. Distinct 
subpopulations of intestinal epithelial cells are integrated into a continuous, single cell layer 
forming the epithelium. The epithelium is divided into apical and basolateral regions that are 
separated by tight junctions, forming a rigorous barrier between gut and blood system. 
Enterocytes form the main cells in the small intestine, and colonocytes the ones in the large 
intestine. Both cell types are polarized and show a typical apical brush border facing the 
intestinal lumen. The intestinal epithelium continuously produces mucus and is covered by it, 
which mainly serves as a defense against microbes. Mucus is generated by goblet cells, 
whereas mucus production is higher in colon as compared to small intestine. The thickness 
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and continuity of intestinal mucus differs regionally. It is thinner and discontinuous in the 
proximal small intestine and becomes thicker and continuous along the colon, showing some 
correlation with the local bacterial load (about 108 organisms/g in the ileum; about 1010–1012 
organisms/g in the colon). The intestinal microbiota plays a crucial role in the cleavage of 
undigested nutrients (e.g. short fatty acids), in the suppression of a pathogenic gut flora as 
well as in the formation of secondary BAs [7]. 
 
1.3 The enterohepatic circulation of BAs 
As aforementioned, the bile is indispensable for the digestion and resorption of lipids and 
lipid-soluble vitamins in the small intestine. Furthermore, it plays an important role in the 
hepatobiliary secretion of endo- and xenobiotic metabolites such as cholesterol or drugs. The 
bile constitutes of BAs (mainly (un)conjugated chenodeoxycholic acid (CDCA), cholic acid 
(CA) and deoxycholic acid (DCA)), bilirubin, cholesterol, phospholipids and heavy metals. 
Due to their amphiphilic character, BAs are able to form mixed micelles together with 
phospholipids being important for lipid and cholesterol solublization [8]. The primary BAs 
CDCA and CA are mainly synthesized from cholesterol and further processed by hepatocytes. 
Upon conjugation with taurine and glycine, an increased hydrophilicity and water solubility is 
reached. Conjugated BA molecules are subsequently excreted from hepatocytes into bile 
ducts, where they are stored in the gallbladder and secreted into small intestine after food 
intake [6]. Over 95% of the excreted BA pool is transporter-dependently reabsorbed in the 
terminal ileum and transported back, over the portal vein, into the liver [9]. In the colon, the 
remaining unconjugated BAs are transformed by bacterial enzymes into the secondary BAs 
DCA and lithocholic acid (LCA), and, to a smaller extent, also into ursodeoxycholic acid 
(UDCA). While LCA is poorly reabsorbed, DCA is easily taken up into enterohepatic 
circulation by passive, facilitated diffusion [8,10].  
Not all hepatocytes contribute equally to BA homeostasis. Based on the distribution of key 
synthetic enzymes across the hepatic acinus, it has been concluded that under normal 
physiological conditions BA synthesis predominantly occurs in hepatocytes surrounding the 
central vein. In contrast, BAs that return from intestine to the liver due to enterohepatic 
circulation are taken up and are transported primarily by periportal hepatocytes [11].  
Besides their crucial role in human physiology, BAs can enfold cytotoxic effects due to their 
detergent properties [12]. Abnormal BA homeostasis has been associated with general liver 
injury, hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), metabolic disorders 
including their hepatic manifestations such as non-alcoholic steatohepatitis (NASH), and 
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diseases of the gastrointestinal tract (e.g. inflammatory bowel disease, colorectal cancer) 
[8,13-15]. Hydrophobic BAs are considered to have a higher cytotoxic potential than the 
hydrophilic BA molecules (hydrophobicity: DCA>CDCA>CA>UDCA) [16]. The 
intracellular accumulation of BAs induces apoptosis or necrosis through nonspecific detergent 
effects and through receptor-mediated interactions of the BA molecules. BA cytotoxicity has 
been linked to stimulation of mitochondrial oxidative stress, generation of reactive oxygen 
species (ROS) and caspase activation - with secondary consequences like inflammation and 
fibrosis. Thereby, c-jun n-terminal kinase (JNK) activation has been discussed to play a 
crucial role in BA-induced cytotoxicity. Furthermore, cyclin D1 has been shown to be a 
relevant player in DCA-induced apoptosis in primary rat hepatocytes [17-20]. In contrast, the 
hydrophilic UDCA counteracts the cytotoxic BA effects - 1) by increasing the elimination of 
hydrophobic BAs out of the enterohepatic circulation and 2) by inhibition of cell apoptosis. 
UDCA is approved as a therapeutic agent against primary biliary cirrhosis and gallstones.  
To avoid cellular damage, BAs function as homeostatic regulators and signaling molecules to 
adjust their own intracellular concentrations [12]. Thereby, BA transporters and their 
transcriptional regulator farnesoid X receptor (FXR) are critical for the maintenance of BA 
homeostasis.  
 
 
2. The metabolic regulator FXR 
FXR is an important member of the nuclear receptor superfamily that plays a crucial role in 
the regulation of BA, lipid and glucose homeostasis. Furthermore, FXR is discussed to act as 
cell protector by promoting liver regeneration, and by elucidating antiapoptotic and anti-
inflammatory effects within organs of the digestive system [21,22]. Figure 2 summarizes the 
most important physiological roles of FXR in the liver and intestine. The mechanisms behind 
are further discussed in the following chapters. 
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Figure 2: Physiological roles of FXR within the human digestive tract. The transcription factor FXR has 
been shown to be a key player in BA homeostasis, lipid metabolism, immune response, and cell growth/death 
regulation in the liver and intestine. BA, bile acid; Foxm1b, forkheadbox m1b; FXR, farnesoid X receptor; JNK, 
c-jun n-terminal kinase; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; ROS, reactive 
oxygen species. 
 
2.1 A ligand-activated transcription factor  
The nuclear receptor FXR is the master regulator of BA homeostasis. It is endogenously 
activated by BAs to prevent intracellular BA accumulation. The hydrophobic CDCA appears 
to be the most efficient FXR activator, whereas DCA and CA are discussed to be partial FXR 
agonists [23]. The CDCA-analogical drug obeticholic acid (OCA, INT-747) is currently tested 
as an FXR activator and as potential therapeutic against primary biliary cirrhosis and NASH 
(www.intercept.com). Thereby, OCA is a 6-α-alkyl-substituted analogue of CDCA and is 
almost 100 times more potent with regard to FXR activation as compared to CDCA [24].  
There are two known FXR genes, FXRα and FXRβ, whereas the FXRβ gene is a pseudogene 
in humans. The FXRα gene has two functional promoters and undergoes alternative splicing 
leading to four possible FXR protein isoforms [22]. MessengerRNA (mRNA) measurement in 
human tissues revealed that FXRα1 (+/- exon 5) is predominantly expressed in the liver, 
whereas FXRα2 (+/- exon 5) is the most abundant isoform in the intestine. FXRα1 and α2 
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differ in their N-terminus as a consequence of two alternative promoters [25]. FXR has a well 
characterized structure with a ligand-binding domain, a DNA-binding domain and two ligand-
(in)dependent transactivation domains. The DNA-binding domain allows FXR to 
transactivate genes via binding to inverted repeat elements. The two transactivation domains 
are responsible for the interaction with co-regulating proteins leading to FXR transactivation 
or repression. FXR can transactivate genes as a monomer, but usually forms a heterodimer 
with retinoid X receptor (RXR) [21,26]. Table 1 summarizes the most important co-regulating 
proteins, ligands and epigenetic modifiers/modifications known to be involved in the 
regulation of endogenous FXR activity.  
 
Table 1: Co-regulating proteins, ligands and epigenetic modifiers/modifications known to be involved in 
the regulation of endogenous FXR activity. 
 
Ligands necessary for FXR-
mediated transactivation 
Transcriptional regulation 
of the FXR gene 
Post-transcriptional regulation  
of FXR expression 
Endogenous ligands 
 Bile acids 
 PGC1α [27] 
 DRIP205 [28] 
 
Synthetic ligands 
 GW4064 
 INT-747 (6-ethyl-CDCA) 
 
 
Factors 
 HNF1α [29] 
 PGC1α-PPARγ [27] 
 PGC1α-HNF4α [27] 
 
Epigenetic modulation 
 CpG island at position -3.2 to        
-2.9 kb upstream of TSS in  
colon cancer [30] 
Epigenetic modulation 
 miR-421 in biliary tract cancer [31] 
 miR-92 in gastric cancer [32] 
 Sirtuin 1 [33] 
CDCA, chenodeoxycholic acid; DRIP, vitamin D-interacting protein; FXR, farnesoid X receptor; HNF, 
hepatocyte nuclear factor; PGC, peroxisome proliferator-activated receptor gamma coactivator; PPAR, 
peroxisome proliferator-activated receptor; TSS, transcription start site. 
 
 
2.2 FXR, the BA sensor 
A disturbed BA-FXR signaling axis is suggested to be important in the pathophysiology of a 
wide range of liver and digestive diseases such as cholestasis, hepatitis or liver and colon 
cancer [21]. In human physiology, BA-activated FXR promotes cellular BA efflux and 
detoxification, and decreases cellular uptake and synthesis via expression regulation of the 
involved transporters and enzymes. In other words, FXR can specifically activate genes to 
counteract BA toxicity. Figure 3 illustrates the enterohepatic circulation of BAs and the FXR-
regulated target genes therein involved.  
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Figure 3: The enterohepatic circulation of BAs. Membrane transporters and other proteins expressed in liver 
and intestine, whose expression is regulated by FXR. Green: FXR-induced protein expression; Orange: FXR-
suppressed protein expression. ASBT, apical sodium bile acid transporter; BSEP, bile salt export pump; CYP, 
cytochrome P450; FGF19, fibroblast growth factor 19; FGFR4, fibroblast growth factor receptor 4; FIC, familial 
intrahepatic cholestasis; FXR, farnesoid X receptor; MDR3, multidrug resistance protein 3; MRP2, multidrug 
resistance-associated protein 2; NOS, nitric oxide synthase; NTCP, Na+-taurocholate cotransporting polypeptide; 
OATP, organic anion transporting polypeptide; OST, organic solute transporter. Figure taken from [12]. 
 
 
Hepatocellular canalicular export of BAs is mainly mediated by the adenosine triphosphate 
(ATP)-binding cassette transporter bile salt export pump (BSEP). It represents the rate-
limiting step of canalicular bile salt export and drives enterohepatic BA circulation [34]. 
Expressions of BSEP, multidrug resistance-associated protein 2 (MRP2) and multidrug 
resistance protein 3 (MDR3), the BA efflux transporters at the apical membrane of 
hepatocytes, have been shown to be directly regulated by FXR [35-37]. Whereas BSEP seems 
to transport mainly (un)conjugated monovalent BAs such as taurocholic acid (TCA), MRP2 is 
responsible for the hepatocellular export of divalent, sulphated or glucuronidated BAs into 
bile [38,39]. MDR3 has a critical role in translocating phospholipids across the membrane and 
thereby promotes mixed micelle formation counteracting BA toxicity in the biliary tree [40].  
In the ileal lumen, BAs are reabsorbed by the apical sodium bile acid transporter (ASBT), the 
major bile salt uptake system in the ileal epithelium [12]. In the colonic lumen, remaining 
unconjugated BAs, particularly DCA, have been suggested to enter colonocytes by passive 
diffusion [13]. BA-dependent FXR activation directly induces the expression of the 
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heterodimeric organic solute transporter (OST) α/β, the major BA efflux transporter in the 
basolateral membrane of entero- and colonocytes, excreting BAs back into portal circulation 
[13,41,42]. OSTα/β transport occurs by facilitated diffusion mechanisms and mediates 
cellular efflux or uptake depending on the electrochemical gradient of the substrate. Further, 
OSTα/β is located in the basolateral membrane of hepatocytes, whereas transport activity 
towards BAs is negligible under physiological conditions. However in cholestatic conditions, 
OSTα/β expression is FXR-dependently upregulated to transport BAs over the hepatic 
basolateral membrane back into blood circulation [18]. The BA-FXR-axis-dependent 
upregulation of OSTα/β as an adaptive response to toxic intracellular BA accumulation has 
been shown to be essential in patients with primary biliary cirrhosis [43].  
FXR also represses the transcription of the three BA synthesizing cytochrome P450 enzymes 
CYP7A1, CYP8B1 and CYP27A1 as response to intracellular BA accumulation in a negative 
feedback loop - in hepatocytes via upregulation of small heterodimer partner (SHP) and in 
enterocytes via the FGF19/FGFR4 pathway. Intestinal FXR activation induces the expression 
of fibroblast growth factor 19 (FGF19), which is subsequently released from the intestine into 
portal blood. FGF19 binds to fibroblast growth factor receptor 4 (FGFR4) on the surface of 
hepatocytes, thus, inducing a FGF19/FGFR4-dependent signaling cascade, which suppresses 
CYP7A1 transcription in the hepatic nucleus [12,44]. SHP is a key player of repressive actions 
of the BA-FXR axis. The FXR/SHP pathway is also involved in the negative expression 
regulation of ASBT and of Na+-taurocholate cotransporting polypeptide (NTCP), the 
predominant Na+-dependent BA uptake transporter in the basolateral membrane of 
hepatocytes. NTCP is responsible for >75% of the (un)conjugated BA uptake. In contrast, the 
organic anion transporting polypeptides (OATP) 1B1 and 1B3 promote the Na+-independent 
hepatic BA uptake [45-47]. The human OATP family consists of 11 members, whereby 
OATP1B1 and OATP1B3 are the OATP transporters predominantly located at the sinusoidal 
membranes of human hepatocytes. Besides, OATP1B3 is also detectable in different types of 
cancer tissue, such as colon, liver, pancreas and lung cancer [48,49]. OATP1B1 and 1B3 are 
membrane transporters that are responsible for the hepatocellular uptake of a number of 
endogenous compounds (e.g. bilirubin, conjugated steroids and eicosanoids) and clinically 
important drugs such chemotherapeutics. OATP1B1 and 1B3 play an important role for the 
pharmacokinetics of several drugs as they precede drug activation and elimination by hepatic 
metabolism or biliary excretion [47,50]. OATP1B1 expression is indirectly and negatively 
regulated by FXR via the SHP/hepatocyte nuclear factor (HNF)-1α pathway, whereas 
OATP1B3 expression is directly activated by FXR. FXR-induced OATP1B3 expression is 
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further discussed to maintain the hepatic extraction of xenobiotics and peptides in case of 
intracellular bile acid accumulation [45,51].  
 
2.3 Lipid metabolism 
Lipids are important nutrient components, which have a dietary origin or are synthesized by 
the liver. 95% of dietary lipids are triglycerides. Other lipids comprise phospholipids, free 
fatty acids, cholesterol, and fat-soluble vitamins. Dietary triglycerides are digested by 
enzymes into monoglycerides and free fatty acids within the gastrointestinal tract, whereas the 
lipid uptake into the circulatory system is facilitated by BA micelles. Endogenously, 
triglycerides and cholesterol are transported through the blood by (very) low and high density 
lipoproteins (VLDL, LDL, HDL), whereas intracellular uptake of these particles is mediated 
by their corresponding receptors [52]. LDL and HDL receptors are expressed in hepatic tissue 
in comparison to VLDL receptor, which is absent from the liver [53,54]. Impaired LDL 
receptor expression has been associated with hypercholesterinemia and subsequent 
atherosclerosis [55].  
Several studies unveiled that BAs play a crucial role in maintaining lipid, glucose and energy 
homeostasis via the activation of proteins such as FXR or the G-protein-coupled receptor 
TGR5 [9,56]. Watanabe et al. showed that FXR/SHP activation plays a role in feedback 
regulation of hepatic fatty acid and triglyceride synthesis, and VLDL production [57]. The 
FXR/SHP pathway further inhibits steroid response element binding protein 1c (SREBP-1c)-
mediated hepatic lipogenesis. Lipogenesis is defined as the process, where acetyl-CoA, a 
conversion product of glucose, is metabolized into fatty acids and subsequently into 
triglycerides. Triglycerides are the main constituents of human body fat [56,57]. In FXR 
knockout mice, hepatic lipids and circulating cholesterol and triglycerides were accumulated, 
whereas FXR activation by agonists decreased plasma cholesterol and triglycerides in wild-
type mice [58,59]. The role of the BA-FXR signaling axis in glucose metabolism is 
controversially discussed in the literature. FXR activation has been associated with improved 
hyperglycemia in diabetic mice [59]. However, the FLINT study, which investigated the 
effects of the FXR activator INT-747 on adult NASH patients, revealed - besides a significant 
improvement in histological NASH features - an increased insulin resistance within 72 weeks 
of INT-747 treatment as well as elevated serum cholesterol concentrations [60]. The BA-
dependent activation of TGR5 and the subsequent increased intestinal secretion of the 
glucagon-like peptide 1 (GLP-1) followed by enhanced insulin release from the pancreas, is 
assumed to be more important in glucose homeostasis as compared to FXR activation [56]. 
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Nevertheless, activation of the BA-FXR signaling axis is still discussed as a possible 
treatment for metabolic syndrome and associated diseases such as non-alcoholic fatty liver 
disease (NAFLD).  
 
2.4 Regulation of the inflammatory response 
Although controlled inflammation is a part of the biological immune response to harmful 
stimuli in human tissues, an uncontrolled and chronic inflammation is a crucial and feared 
mechanism that is involved in the progression of many liver and digestive diseases such as 
NAFLD, viral hepatitis, drug-induced liver injury or inflammatory bowel disease. Preceding 
chronic tissue inflammation has been linked to cancer development throughout the whole 
human digestive system. After lipopolysaccharide (LPS) administration to FXR knockout 
mice, the murine hepatic tissue developed massive necrosis and inflammation, whereas no 
significant liver damage could be observed in wild-type animals. Mice with constitutively 
hepatic expression of FXR after adenoviral VP16-FXR tail injection showed decreased 
inflammatory response to LPS injection. In this context, it could be demonstrated that FXR is 
a negative modulator of nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB)-
mediated hepatic inflammation [61]. NF-κB is a nuclear transcription factor that enhances the 
expression of inflammatory markers such as tumor necrosis factor (TNF) α or interleukin 
(IL)-1β [21]. Excessive intracellular BA accumulation has been linked to the activation of the 
NF-κB signaling pathway in liver and colon cells, showing more uncontrolled liver 
inflammation in FXR knockout mice as compared to wild-type animals. These findings 
confirm the hepatoprotective effects of FXR regarding uncontrolled activation of 
inflammatory processes [62,63]. 
 
2.5 Impact on normal and pathological cell growth 
The exact role of FXR in cell growth regulation, apoptosis and carcinogenesis is still not fully 
elucidated. The published literature regarding hepato- and intestine-protective effects of FXR 
in cancerogenesis are mainly based on FXR-knockout animal studies. Kim et al. for example 
showed that FXR-null mice exhibited elevated serum and hepatic BA levels, an increased 
inflammatory response and a higher incidence of hepato(cholangio)cellular carcinoma [64]. In 
mouse intestine, loss of FXR expression and subsequent elevations of intestinal BA levels led 
to earlier mortality caused by increased tumorigenesis. Unlike in the liver, intestinal FXR 
expression loss itself seemed to increase tumor susceptibility and not merely the subsequently 
elevated BA concentrations [65]. FXR is assumed to be a direct suppressor of the Wnt/β-
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catenin pathway leading to decreased cyclin D1 expression [66]. FXR is further discussed to 
act as a suppressor of the JNK/c-jun pathway via suppression of ROS production [67]. In 
contrast, pathways involving increased cyclin D1 and c-jun expressions are also debated as 
promotors of apoptotic processes, dependent on concomitant signals (e.g. BA-mediated; q.v. 
para. 1.3) and the cell type [68-70]. These findings are in line with reports showing that FXR 
activation reduces inflammatory, apoptotic and fibrotic processes in NASH [71]. Further, 
FXR activation improved defective regeneration in aging mouse livers via FXR-dependent 
induction of forkheadbox m1b (Foxm1b) expression. Foxm1b is a proliferative transcription 
factor required for normal liver regeneration, which is inversely correlated with apoptosis and 
is highly upregulated in human HCC as compared to non-tumorous livers [21,72,73]. These 
cited studies highlight the ambivalent role of FXR in cell growth regulation and further 
research is necessary to elucidate the real role of FXR in carcinogenesis. 
 
 
3. MicroRNAs and their regulatory role in the human digestive system 
3.1 Epigenetic, post-transcriptional regulators of gene expression 
Besides DNA methylation and histone modification, microRNAs (miRNAs, miRs) belong to 
the epigenetic regulatory network, which coordinates the expression of the human genome. It 
has been estimated that expression of 60% of all human genes are miRNA-dependently 
regulated [74]. To date, the miRBase database lists 1881 human precursor miRNA sequences 
(www.mirbase.org). MiRNAs are short non-coding RNA molecules of 18–25 nucleotides in 
length, which regulate target gene expression on a post-transcriptional level [75,76]. Figure 4 
illustrates the endogenous formation of mature miRNA molecules. Every miRNA molecule 
contains a seed sequence (nucleotides 2-7) that particularly matches with sites located within 
the 3’ untranslated region (UTR) of a mRNA [74]. Usually, only one mature miRNA strand is 
formed in vivo, whereas the other strand of the miRNA duplex molecule is degraded. But, at 
least 80 different human miRNA precursors can yield two abundant, functional relevant, 
mature miRNAs - a 5′ strand (-5p) and a 3′ strand (-3p) with different seed sequences and 
mRNAs as binding targets. However, there is increasing evidence for interplay between the 5’ 
and the 3’ strand arm of the same precursor molecule targeting the same group of genes and 
reinforcing one certain phenotype [77]. The pleiotropic effects of miRNA molecules, meaning 
their ability to regulate the expression of a large set of target genes in parallel, illustrate a 
currently discussed problem in the consideration of miRNAs as potential therapeutics.  
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Figure 4: Biogenesis and function of miRNAs. Almost all miRNA genes are transcribed by the RNA 
polymerase II into pri-miRNAs, which are long transcripts including multiple hairpin loop structures. Pri-
miRNAs are further processed into pre-miRNAs by the Microprocessor protein complex containing the RNase 
Drosha. Pre-miRNAs are precursor molecules of 70-80 nucleotides in length that contain a characteristic hairpin 
loop structure. These precursors are then further exported from the nucleus into cytoplasm by exportin 5. There, 
pre-miRNAs are processed by the RNase Dicer into short, double-stranded miRNAs, which are then converted to 
mature, single-stranded miRNAs via RNA-induced silencing complex (RISC). RISC is a protein complex that 
contains argonaute (AGO) proteins. Finally, mature miRNAs direct RISC to target mRNAs, leading to their 
degradation (when perfect complementary binding) or translational repression (when imperfect complementary 
binding). AGOs are the catalytic enzymes with endonuclease activity that are responsible for target mRNA 
degradation. Adapted from [78]. 
 
 
3.2 Physiological and pathological roles 
About 1400 human mature miRNAs are described in the literature, for which sufficient 
evidence exists for an important role in normal human development, cell differentiation and 
cell growth control [79]. MiRNA molecules are already entering the clinic as diagnostic and 
prognostic biomarkers and further as therapeutic targets and agents referring to several 
diseases of the human digestive system such as (steato)hepatitis, cholestasis, drug-induced 
liver injury, (cholangio)hepatocellular carcinoma, cholangiocarcinoma, colon cancer or 
inflammatory bowel disease. The (patho)physiological role of miRNAs in the regulation of 
key-cancer pathways such as cell cycle control is currently mostly discussed in the literature. 
In this context, the liver-relevant miR-192 and miR-34a have reached attention because of 
their ability to interact with the tumor protein p53 [79]. p53 (TP53) has been dubbed the 
“guardian of the genome” that mediates apoptosis and tumor suppression [80]. The 
transcription factor p53 is the most frequently mutated gene in human cancers, whereby 
mutations often lead to a reduced or completely abolished transcriptional function of this 
protein [81]. Pichiorri et al. provided evidence that miR-192 is transcriptionally activated by 
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p53, thus, modulating the expression of the mouse double minute 2 homolog (MDM2), a 
negative regulator of p53 [82]. Alternative miRNAs have further been described to influence 
this MDM2/p53 feedback loop such as miR-509 or miR-122-3p [83,84]. Comparable to the 
miR-192/MDM2/p53 interaction, a similar interplay has been shown for miR-34a. p53 can 
activate the transcription of miR-34a, which in a consequence leads to a suppression of 
nicotine adenine dinucleotide-dependent deacetylase sirtuin-1 (SIRT1) expression. Through 
this mechanism, decreased SIRT1-dependent deacetylation of p53 is leading to an increased 
p53 function, but, however, also to more acetylated FXR [33,79]. Acetylation of FXR 
increases its stability, but inhibits its heterodimerization with RXRα and transactivation 
ability. However, SIRT1 overexpressing mice, which anamnestically underwent partial 
hepatectomy, revealed decreased FXR, SHP and BSEP protein expressions [85]. Based on 
this finding, other SIRT1-dependent epigenetic modifications such as histone deacetylation, 
may influence FXR activity and conclusions about any functional relevance of the miR-
34a/SIRT1 interplay on FXR activity are currently difficult to draw.  
There are further target mRNAs that are described to be (in)directly regulated by miR-192 or 
miR-34a. The ones, which play a relevant role in cell cycle regulation of liver and intestinal 
cells, are summarized in Figure 5.  
 
 
Figure 5: (In)direct target mRNAs of the p53-regulated miRNAs -192, -509 and -34a, which play a crucial 
role in cell cycle arrest and apoptosis. All three miRNAs form a positive feedback loop with the endogenous 
cell cycle regulator p53. BCL-2, B-cell lymphoma 2; FXR, farnesoid X receptor; MDM2, mouse double minute 
2 homolog; SIRT1, sirtuin 1; ZEB2/SIP1, zinc finger E-box binding homeobox 2/Smad interacting protein 1; 
[33,82,86-89]. 
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4. Transcriptional and miRNA dysregulation in hepatic and intestinal 
diseases 
 
A disturbed BA-FXR signaling axis and shifts in expression of p53-dependently regulated 
miRNAs are both discussed in the literature to play a pivotal role in diseases of the human 
digestive system, where mainly cell cycle regulatory processes are pathologically involved. 
Figure 6 gives an overview of known causes promoting the progression of different liver 
diseases, including changed miRNA expression levels and a disturbed BA-FXR signaling 
axis. As such alterations are additionally well described for colon carcinogenesis, we will 
focus in the next paragraphs on FXR-/miRNA-dependent pathomechanisms involved in 
cholestasis, NAFLD, liver and colon cancer.  
 
 
Figure 6: Summary of known causes leading to liver damage, cirrhosis and liver cancer development. In 
all liver disease-stages changed expression levels of p53-controlled miRNAs (e.g. miR-192, miR-34a) or an 
altered BA-FXR signaling axis are described to promote disease progression. An imbalance between apoptosis 
and liver regenerative processes can promote liver inflammation leading to uncontrolled hepatocyte growth, 
formation of excess fibrous connective tissue, oxidative stress, and subsequent irreversible cirrhotic liver and/or 
tumorigenesis. Yellow: known causes of non-alcoholic liver disease (NAFLD), hepatitis, cholestasis or other 
liver injuries. BA, bile acid; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; 
NASH, non-alcoholic steatohepatitis; ROS, reactive oxygen species. Adapted from [90]. 
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4.1 Cholestatic liver 
Cholestasis is characterized by impaired bile secretion and/or bile flow between liver and 
duodenum, which leads to an accumulation of BAs in hepatocytes and the intrahepatic bile 
duct system (intrahepatic cholestasis) or in the extrahepatic biliary tract (extrahepatic 
cholestasis). Intracellular hepatic BA accumulation can promote inflammation, fibrosis, 
cirrhosis and subsequent tumorigenesis in the liver (Fig. 6). The most important hepatic, 
compensatory anticholestatic response is the BA-dependent FXR activation and the 
subsequent changes in BA homeostasis (q.v. para. 1.2.2). It has been hypothesized that a 
decreased BA level in the intestinal lumen leads to an insufficient intestinal FXR/FGF19 
response, which induces an inappropriate hepatic BA neosynthesis and progressive liver 
damage in cholestatic patients [21,91]. Rare mutations in genes coding for BA transporters 
located in the canalicular membrane of hepatocytes are known that result in intrahepatic 
cholestasis: e.g. progressive familial intrahepatic cholestasis PFIC2 due to an impaired 
function of BSEP [92]. Genetic variations in NR1H4, the gene coding for FXR, were 
associated with intrahepatic cholestasis of pregnancy [93]. Until now, no studies are available, 
which investigate the miRNA-dependent regulation of FXR expression in the context of BA 
homeostasis. Instead, miR-33 has been observed to regulate the expression of BSEP and 
elevated miR-33 levels have been shown to have a functional relevance by disturbing the 
canalicular BA secretion in mice [94]. Furthermore, upregulation of miR-34a and the 
subsequent impact on SIRT1 expression has been associated with BA-induced tissue injury 
[95] based, however, on NAFLD rat model studies [96]. Lee et al. observed that FXR 
suppresses miR-34a expression via binding of SHP to its promoter, which thereby inhibits 
promoter occupancy of p53 [33]. But there are no studies in the literature, which reveal a 
direct link between changed miR-34a expression levels and intrahepatic cholestasis formation. 
Although not yet sufficiently investigated, we hypothesize that miRNAs play a key role in the 
maintenance of BA homeostasis and in the pathophysiology of intracellular BA accumulation, 
i.a. via their interactions with FXR.  
 
4.2 Non-alcoholic fatty liver disease 
NAFLD is a common and increasing cause of chronic liver disease in the Western world, 
affecting up to 30% of all Americans [97]. NAFLD is characterized by an abnormal 
accumulation of triglycerides in hepatocytes leading to liver steatosis in the initial stage [6]. 
NASH is characterized by hepatic inflammation, which promotes the development of fibrotic 
liver tissue [97]. NASH progresses in 15–20% to cirrhosis. It is a rising indication for liver 
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transplantation and is associated with an increased risk for HCC. Obesity, diabetes, metabolic 
syndrome and insulin resistance are risk factors leading to NAFLD [21,97]. At present, there 
are no pharmacological treatments approved for NASH [60,98]. When bound to FXR, 
lipophilic BAs reduce circulating triglycerides levels due to inhibition of lipogenesis. Besides 
stimulation of FXR activity, BA-dependent activation of TGR5 is further discussed as 
possible pharmacological target for the treatment of NAFLD (q.v. para. 2.3) [56,60,99]. In 
addition to the FXR ligand INT-747, a BA-modified dual FXR/TGR5 agonist (INT-767) is 
currently investigated as a potential treatment for NAFLD-associated fibrosis 
(www.interceptpharma.com).  
Histological features of cholestasis are not typical for NAFLD, which suggests the co-
existence of another liver disease if present. However, there are several mouse and human 
NAFLD studies showing that a concomitant dysfunction of the FXR/SHP pathway results in 
moderately increased BA levels and promotes the inflammatory cascade and the progression 
of NASH [21,100-103]. Aranha et al. showed that hepatic DCA, CDCA and CA levels were 
moderately elevated by 92, 64, and 43%, respectively, in patients with steatohepatitis as 
compared to healthy controls. Furthermore, significant correlations were found between 
hepatic CDCA levels and fibrosis in NASH patients conferring an association between 
specific BAs and disease progression, possibly through BA-induced liver injury [104].  
As JNK-dependent hepatocyte lipoapoptosis is claimed to be a key feature in NAFLD [105], 
the potential involvement of apoptosis-related miRNAs has to be highlighted here. In mouse 
models and humans, an elevated expression of miR-122, miR-192 and miR-34a are discussed 
as potential serum biomarkers in NAFLD [106]. In steatosis, hepatic miR-192 and miR-122 
expression levels were increased as compared to healthy liver tissue and as compared to tissue 
obtained from NASH patients. Pirola et al. claimed that the overall miR-192/-122 expression 
is elevated in NAFLD. With progression of liver injury, an increased release of these two 
miRNAs into serum was observed [107]. Beside chronic inflammatory processes, enhanced 
miR-192 expression was further associated with transforming growth factor (TGF)-β/Smad 
signaling-driven fibrosis [108]. Also hepatic miR-34a expression increased, SIRT1 expression 
decreased and the levels of acetylated p53 progressively rose with NAFLD disease severity in 
obese patients [96]. In fatty liver of obese mice, a disturbed FXR/SHP pathway was 
associated with the increased miR-34a expression levels [33]. In line with these observations, 
Panasiuk et al. showed that intensification of NAFLD-associated inflammation induces the 
cell cycle regulator p53 [109]. Based on these findings we hypothesize that the p53-regulated 
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miRNAs miR-34a and miR-192 as well as a disturbed FXR/SHP pathway play a crucial role 
in the progression of NAFLD. 
 
4.3 Malignancies 
4.3.1 Hepatocellular carcinoma 
Malignant tumors of the liver are classified in primary and secondary (metastatic, e.g. 
originated from colorectal cancer) malignancies. HCC, a cancer formed by hepatocytes, is 
accounting for approximately 75% of all primary liver cancers. 6% of primary liver 
malignancies are cholangiocarcinoma, originating from the intrahepatic bile ducts [110]. As 
shown in Figure 6, HCC usually develops on the basis of abundant chronic liver diseases. 
Main causes are chronic hepatitis B and C, but HCC can also be the end stage disease of 
cholestatic liver or non-viral hepatitis. The link between cholestatic liver disease and liver 
cancer has already been established in clinical studies. E.g. children with mutated BSEP 
suffering from PFIC2 were prone to liver tumor formation [111]. Furthermore, there is 
increasing evidence that NAFLD is frequently underlying liver cancer development [112]. 
HCC is as a very aggressive tumor and often diagnosed late in its course because of the 
absence of pathognomonic symptoms. Additionally, HCC is considered to be a relatively 
chemotherapy-refractory tumor, with sorafenib as the established standard monotherapy. 
Platin derivates are used as second-line therapy. Consequently, HCC is the second leading 
cause of cancer-related death in men [113].  
As aforementioned, the role of FXR in carcinogenesis is still not clear. However, several 
authors discuss a cancer-protective role of FXR based on results obtained from FXR-null 
animal models. Additionally, several studies showed reduced FXR expression in human HCC 
tissues as compared to non-tumorous tissue [114,115]. In contrast, an immunohistochemical 
study observed a preserved or enhanced FXR protein expression in tumor cell nuclei of 
human HCC tissue compared with hepatocyte nuclei of normal and diseased liver [116].   
Hundreds of epigenetic pathways, including miRNAs, are described in the literature to be 
disturbed in HCC. The high number of published in vitro and in vivo studies illustrates the 
complicated network underlying carcinogenesis. Currently, miR-34 mimic replacement 
therapy (MRX34) is investigated in phase I drug development stage as the first miRNA-based 
treatment against primary and secondary liver cancers [117]. The p53/miR-34 pathway is 
discussed to be involved in the development of different cancers such as liver and colon 
tumors, showing a downregulated miR-34a expression as compared to non-tumorous tissue. 
In vitro studies performed in liver and colon cancer cell lines showed a miR-34a-dependent 
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suppressive effect on cell growth, invasion and migration [88,118]. Although, miR-192 is not 
considered to be typically changed in expression in several studies on HCC, Lian et al. 
observed a significantly suppressed expression of miR-192 in HCC tissue as compared to 
non-tumorous tissue [119]. 
 
4.3.2 Colon carcinoma 
Most of the malignant, polypoid-ulcerating intestinal tumors are adenocarcinoma, originating 
from glandular cells of the intestinal mucosa [6]. Colorectal cancer (CRC) is the fourth 
leading cause of cancer-related death in men. In the last years, a trend towards decreased 
mortality can be attributed to more CRC screening and improved cancer prevention and 
treatments. Effective, adjuvant standard therapeutics are for example platin derivates such as 
oxaliplatin and 5-fluorouracil in combination with folinic acid, or irinotecan. Risk factors for 
developing CRC are of genetic and environmental origin such as obesity, physical inactivity 
and a high consumption of red and processed meat [113]. Furthermore, there is a well-
documented association between inflammatory bowel disease and colonic neoplasia. It has 
been claimed that high fat diet modifies the progression of colon cancerogenesis by increasing 
the amount of serum and fecal BAs. Particularly, DCA and LCA have been strongly 
associated with colon tumorigenesis as they affect the colonic epithelium via promotion of 
DNA oxidative damage, inflammation, and enhanced cell proliferation [13,21,120]. In healthy 
tissues, FXR expression gradually increases from terminal ileum to the sigmoid colon. In 
colon carcinoma, FXR levels are reduced as compared to peritumoral nonneoplastic mucosa 
and were inversely correlated with tumor stage [121]. In mouse intestine, knockout of FXR 
expression resulted in elevated intestinal BA concentrations, an increased inflammatory 
response and earlier mortality because of increased tumor progression [65].  
MiR-192 is hypothesized to be a risk biomarker for colon cancer-originated liver metastasis as 
well as a high-potential drug agent for primary colon cancer [87]. Loss of p53 function by 
mutation and consequently decreased miR-192 and miR-34a expressions might play a crucial 
role in colon cancerogenesis [122,123]. Similarly to liver cancer, several hundred miRNAs 
are described in the literature to be involved in colon tumorigenesis, which underlines the 
need for more human studies investigating the real endogenous role of certain miRNAs in 
liver and colon cancerogenesis. 
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5. Objectives of the thesis 
Little is known about the bidirectional interaction between the BA sensor FXR and miRNAs 
in diseases of the human digestive system. The overall aim of this thesis was to investigate 
changes in the functionality of the BA-FXR axis based on shifts in miRNA expression and the 
impact of this interplay on metabolic pathways and cell cycle regulation. We aimed to study if 
FXR and FXR target genes are epigenetically regulated by miRNAs and, as a consequence, if 
a disturbed BA-FXR axis might influence the endogenous miRNA network in vitro and in 
vivo. By elucidating the miRNA-dependent epigenetic pathways involved in the regulation of 
endogenous FXR activity, opportunities for potential novel therapeutics against liver and 
intestinal diseases shall be discussed.  
 
 
6. Structure of the thesis 
In Chapter 1 we demonstrate that BA-FXR-controlled signaling influences the endogenous 
miRNA network involved in metabolic and cell cycle regulation-associated pathways of the 
liver. CDCA-dependent activation of the BA-FXR signaling axis significantly impacts the 
expression of miRNAs and genes involved in lipid, BA and drug metabolism in primary 
human hepatocytes. Furthermore, this chapter illustrates a link between the apoptotic, p53-
regulated miRNA miR-34a and BA homeostasis in dependence of FXR transactivation. 
In Chapter 2 we show that FXR and FXR target genes, all of which are important in the 
maintenance of BA homeostasis, are epigenetically regulated by the p53-regulated miRNA 
miR-192. Besides, the cell cycle-regulatory role of the miR-192/FXR interplay on 
proliferation of liver and colon cancer cells is elucidated. 
In Chapter 3, an additional direct miRNA-dependent expression regulation of the FXR target 
gene OATP1B3 is demonstrated. This chapter highlights the complexity of the endogenous 
miRNA gene regulatory network by showing a “multiple-to-one” relationship between 
miRNAs and OATP1B3 expression.  
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Aims: Bile acids (BAs) are important gut signaling hormones, inﬂuencing lipid, glucose, and energy homeostasis.
The exact mechanisms behind these effects are not yet fully understood. Lately, they have come to the fore as
putative therapeutics in metabolic diseases, such as e.g. nonalcoholic fatty liver disease (NAFLD). We elucidate
to what extent BAs impacts on the mRNAome and microRNAome in hepatocytes to gather novel insights into
the mechanisms behind metabolic and toxicologic effects of bile acids.
Main methods: Five batches of primary human hepatocytes were treated with 50 μmol/l chenodeoxycholic acid
(CDCA) for 24 or 48 h. Total RNA was extracted, size fractionated and subjected to Next Generation Sequencing
to generate mRNA and miRNA proﬁles.
Key ﬁndings: Expression of 738 genes and 52 miRNAs were CDCA dependently decreased, whereas 1566 genes
and 29 miRNAs were signiﬁcantly increased in hepatocytes. Distinct gene clusters controlling BA and lipid ho-
meostasis (FGF(R), APO and FABP family members, HMGCS2) and drug metabolism (CYP, UGT and SULT family
members) were signiﬁcantly modulated by CDCA. Importantly, CDCA affected distinct microRNAs, including
miR-34a, -505, -885, -1260 and -552 that systematically correlated in expression with gene clusters responsible
for bile acid, lipid and drug homeostasis incorporating genes, such as e.g. SLCO1B1, SLC22A7, FGF19, CYP2E1,
CYP1A2, APO family members and FOXO3.
Signiﬁcance: Bile acids signiﬁcantlymodulatemetabolic and drug associated gene networks that are connected to
distinct shifts in the microRNAome These ﬁndings give novel insights on how BA enfold metabolic and system
toxic effects.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Bile acids (BAs) are important endogenous compounds responsible
for the efﬁcient absorption of lipid-soluble compounds in the intestine.
Semiquantitative BA derivatives, such as e.g. obeticholic acid (OCA), are
currently discussed as future treatment option for different metabolic
diseases, such as non-alcoholic fatty liver disease (NAFLD), the most
common liver disease in the western world [1]. There is an urgent
need to better understand how BAs enfold their effects on metabolic
pathways and on their own homeostasis to better estimate safety and
efﬁcacy of these compounds.
The effects of BAs on metabolism are triggered by their interaction
with the nuclear receptor FXR, which leads to improvement of steatosis
and ﬁbrosis in NAFLD [1,2] and a bettering of hepatic insulin sensitivity
[3]. By interactingwith FXR, BAs also regulate their ownhomeostasis via
negative and positive feedback loops [4], thus preventing cells from an
Life Sciences 156 (2016) 47–56
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intracellular BA overload with toxic effects [5]. The enterohepatic circu-
lation and homeostasis of BAs are ensured by a coordinated action of BA
uptake and efﬂux transporters. Bile acid transporters include amongst
others the apical sodium-dependent bile acid transporter (ASBT) and
organic solute transporters ɑ/β (OSTα/β) in the intestine, and the
Na+-taurocholate co-transporting polypeptide (NTCP), the organic
anion-transporting polypeptides OATP1B1 and OATP1B3 and the bile
salt export pump (BSEP) in hepatocytes [6].
As ligands for the nuclear receptors FXR, PXR or CAR, BAs regulate
the expression of several genes that are important for both BA homeo-
stasis and drug metabolism, such as e.g. OATP1B1, OATP1B3 and
CYP3A4. This effect may give space for interactions between BAs and
therapeutics and may affect drug exposure margins with consequences
for drug safety and efﬁcacy. By interacting with several other receptor
molecules, besides FXR, such as muscarinic receptors or G protein-
coupled receptors (i.e. TGR5) [7,8], BAs inﬂuence lipid and energy ho-
meostasis. TGR5 triggers weight loss upon activation by BAs [9–11]
and has a positive impact on glucose tolerance by inducing the secretion
of glucagon-like-peptide 1 (GLP-1) from intestinal enteroendocrine
cells [12].
Notwithstanding the role of genetic susceptibility factors in the
pathogenesis of obesity and diabetes [13–16], the complex interplay of
genetically, epigenetically andmicroRNA (miRNA)-driven factors is be-
coming increasingly evident [17–20]. In particular, shifts in the concen-
trations of miRNAs, small noncoding molecules that inhibit mRNA
translation, can lead to rapid changes in protein expression [21].
MiRNAs belong to a relatively small pool of molecules controlling the
expression of major parts of the genome. Thus, expression changes of
only fewmiRNAs can broadly impact the functional integrity of different
metabolic and signaling pathways.
In the current study we investigate the effect of the BA cheno-
deoxycholic acid (CDCA) on the expression of the miRNAome and
mRNAome in primary human hepatocytes (PHHs) and assess to what
extent CDCA induces systematic shifts in gene networks responsible
for BA and lipid homeostasis as well as drug metabolism. BA-induced
shifts in the miRNA proﬁle are set in context to the investigated net-
works to elucidate novel miRNA driven regulatory pathways inﬂuenc-
ing the expression of the mentioned gene networks.
2. Material and methods
2.1. Primary human hepatocytes (PHH)
The study was approved by the Ethics Committee of the Canton of
Zurich, Switzerland (study number EK-680) and the Human Tissue
and Cell Research (HTCR) Foundation. The HTCR-process that included
written informed consent was approved by the Ethics Committee of
the Medical Faculty of the Ludwig Maximilians University (approval
number 025-12) and complied with the Bavarian Data Protection Act.
PHH were obtained from ﬁve patients in Germany who were
Table 1
Clinical characteristics of liver cell donors.
Patient No Gender Age Main diagnosis drugs
1 Female Between 71 and 80 Colon carcinoma and liver metastases None
2 Female Between 70 and 79 GIST tumor None
3 Female Between 51 and 60 Rectosigmoid carcinoma with liver metastases State after 6 cycles of oxaliplatin/folinic acid(FUFOX)
Avastatin
4 Female Between 51 and 60 Liver metastasis after kidney cancer Bisoprolole
L-thyroxine
Zopiclone
Anagrelide
5 Female Between 31 and 40 Hepatocellular carcinoma Metamizole
Fig. 1. Gene enrichment analysis showing signaling pathways most affected by CDCA.
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undergoing liver resection because of liver metastases in association
with primary tumors in colon or kidney or because of hepatocellular
carcinoma. The clinical characteristics of the patients are summarized
in Table 1 (supplementary information). PHHs were prepared as earlier
described [22] and kept in six-well plates in hepatocyte maintenance
medium supplemented with UltraGlutamine for approximately 5 h be-
fore further treatment procedures. PHHswere cultured at 37 °C in a hu-
midiﬁed atmosphere containing 5% CO2 at atmospheric pressure.
2.2. Cell treatment and whole RNA isolation
PHHs of 5 patients were kept in 6 well plates. 24 h later duplicate
wells of each cell batch were treated with chenodeoxycholic acid
(CDCA) or dimethyl sulfoxide (DMSO) (vehicle control) (both from
Sigma-(both from Sigma-Aldrich, Buchs, Switzerland). One CDCA and
one DMSO treated well of each cell batch were harvested together
24 h or 48 h after cell treatment using TRIzol reagent (Invitrogen, Carls-
bad, CA, USA) for combined DNA and RNA isolation. Subsequently, total
RNA was puriﬁed using the miRNeasy kit from Qiagen (QIAGEN,
Hombrechtikon, Switzerland).
2.3. Next generation sequencing
For library preparation the quality of the isolated RNAwas evaluated
using a Qubit® (1.0) Fluorometer (Life Technologies, Carlsbad, CA, USA)
and a Bioanalyzer 2100 (Agilent, Waldbronn, Germany). Only those
samples with a 260 nm/280 nm ratio between 1.8 and 2.1 and a 28S/
18S ratio of 1.5–2 were further processed. 3′ and 5′ RNA adapters
were ligated to total RNA samples (1 μg) using the TruSeq small RNA
Sample Prep Kit v2 (Illumina, Inc., San Diego, CA, USA). Ligated samples
were reverse-transcribed into double-stranded cDNA and fragments
containing TruSeq adapters on both ends were selectively enriched by
polymerase chain reaction (PCR). The small RNA fraction (145–160 bp)
was selected and isolated by polyacrylamide gel electrophoresis. The
quality and quantity of the enriched libraries were validated using a
Qubit® (1.0) Fluorometer and the Caliper GX LabChip® GX (Caliper
Life Sciences, Inc., Hopkinton, MA, USA). The libraries were diluted to
10 nM in Tris-Cl 10 mM, pH 8.5 with 0.1% Tween 20. For cluster genera-
tion and sequencing the TruSeq PE Cluster Kit v3-cBot-HSwas usedwith
10 pMof pooled normalized libraries on the cBOT system (Illumina, Inc.).
Sequencingwas performed on the Illumina HiSeq 2000 using the TruSeq
SBS Kit v3-HS (Illumina, Inc.).
Table 3
Effect of CDCA on the expression of genes involved in lipid homeostasis in primary human
hepatocytes after 48 h.
Gene name⁎ log2 ratio Fold change p-Value FDR
Bile acid dependently up-regulated genes
FABP3 2.981 7.9 0.0001 0.009
APOL3 1.464 2.76 1.50E-10 1.09E-07
FGFR2 1.42 2.68 8.02E-06 0.001
LDLR 1.339 2.53 4.20E-13 6.58E-10
PPARD 1.256 2.39 2.18E-06 b0.001
FGF21 1.25 2.38 0.0281 0.347
FASN 1.185 2.27 0.0081 0.174
PCSK9 1.182 2.27 3.95E-06 0.001
S1PR2 1.146 2.21 0.0122 0.224
S1PR1 0.9341 1.91 2.49E-05 0.003
PRKCE 0.8938 1.86 0.0019 0.073
APOA2 0.8007 1.74 0.003 0.098
SCARB1 0.691 1.61 0.0017 0.068
CPT1A 0.6706 1.59 0.0018 0.071
SREBF2 0.6289 1.55 0.0071 0.162
LDLRAP1 0.6005 1.52 0.0061 0.149
NPC1 0.5843 1.5 0.0024 0.085
NPC1L1 0.5734 1.49 0.0014 0.061
SLC27A2 0.5539 1.47 0.0034 0.106
STARD3 0.5293 1.44 0.02643 0.336
FGF2 0.526 1.44 0.02203 0.305
PRKCA 0.5093 1.42 0.0053 0.137
FOXO3 0.5087 1.42 0.0284 0.349
AGPAT2 0.5037 1.42 0.0187 0.281
CREBBP 0.45 1.37 0.0355 0.391
FGFRL1 0.4191 1.34 0.0493 0.459
ATF6B 0.416 1.33 0.0352 0.389
Bile acid dependently down-regulated genes
ACAT1 −0.432 0.74 0.02 0.291
PEX3 −0.4953 0.71 0.0115 0.216
AKR7A3 −0.5941 0.66 0.0041 0.118
APOM −0.6031 0.66 0.0064 0.151
ACADSB −0.6303 0.65 0.0008 0.042
APOC4 −0.7548 0.59 0.0086 0.182
AKR1C1 −0.8871 0.54 0.0161 0.261
APOH −0.9548 0.52 0.0004 0.027
ANGPTL3 −0.9995 0.5 0.0009 0.045
ACAD11 −0.9997 0.5 2.95E-07 8.36E-05
APOA4 −1.059 0.48 0.0135 0.239
AKR1C4 −1.069 0.48 7.84E-08 2.66E-05
FABP7 −1.964 0.26 0.0051 0.134
HMGCS2 −2.128 0.23 0.0001 0.01
⁎ Genes involved in lipid homeostasis (FDR b 0. 46 and p-value b 0.05).
Table 2
Effect of CDCA on the expression of genes involved in bile acid homeostasis and drugme-
tabolism in primary human hepatocytes after 48 h.
Gene name⁎ log2 ratio Fold change p-Value FDR
Up-regulated genes
Bile acid homeostasis
FGF19 5.078 33.78 3.541xE-07 9.624xE-05
SLC51B 4.934 30.57 1.091xE-15 2.958xE-12
NR0B2 2.85 7.21 9.207xE-11 8.158xE-08
ABCB11 2.195 4.58 2.194xE-09 1.177xE-06
SLC51A 2.194 4.58 8.15xE-16 2.768xE-12
ABCB4 1.603 3.04 5.099xE-10 3.149xE-07
ABCG5 0.8736 1.83 0.0015 0.065
SLCO1B3⁎⁎ 0.5981 1.51 0.0045 0.124
ABCG8 0.4935 1.41 0.0438 0.434
Drug metabolism
UGT2B10 1.264 2.4 0.0006 0.033
SULT1C2 1.13 2.19 0.0393 0.412
UGT1A8 0.9499 1.93 0.021 0.298
UGT2B4 0.7462 1.68 0.0098 0.196
UGT1A3 0.5976 1.51 0.0269 0.34
UGT1A1 0.5671 1.48 0.0416 0.425
PPARG 0.5001 1.41 0.0431 0.432
Down-regulated genes
Bile acid homeostasis
EPHX1⁎⁎ −0.4618 0.73 0.035 0.389
NR1I3 −0.5675 0.67 0.0106 0.207
SLCO1B1 −0.5869 0.67 0.0046 0.126
BAAT −0.8562 0.55 0.0035 0.107
CYP3A4⁎⁎ −1.734 0.3 2.055xE-13 3.49xE-10
CYP7A1 −6.271 0.01 9.197xE-18 4.686xE-14
Drug metabolism
AHR −0.4569 0.73 0.0413 0.423
UGT1A6 −0.5588 0.68 0.0127 0.229
NR1I3 −0.5675 0.67 0.0106 0.207
SLCO1B1 −0.5869 0.67 0.0046 0.126
UGT2A3 −0.7303 0.6 0.0026 0.09
SULT1B1 −0.7455 0.6 0.0017 0.067
UGT1A7 −0.9585 0.51 0.0423 0.429
SLC22A7 −1.054 0.48 0.0189 0.282
CYP2C8 −1.605 0.33 8.14E-07 b0.001
SULT1E1 −1.679 0.31 0.0014 0.063
SLC22A1 −1.726 0.3 8.55E-12 1.09E-08
CYP1A2 −1.921 0.26 1.05E-07 3.23E-05
CYP1A1 −1.954 0.26 1.96E-05 0.002
UGT1A9 −2.095 0.23 6.84E-05 0.007
CYP2E1 −2.556 0.17 2.03E-21 2.07E-17
⁎ Genes involved in drug metabolism or bile acid homeostasis with a FDR b 0. 46 a
p-value b 0.05.
⁎⁎ Involved in both bile acid homeostasis and drug metabolism or drug transport.
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2.4. Processing of NGS data
RNA sequence reads were quality-checked using the software pack-
age fastqc (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/
) which computes various quality metrics for the raw reads.
MessengerRNA sequencing reads were aligned to the genome and
transcriptome using the R statistics package tophat v. 1.3.3 with default
options. Beforemapping, the low quality ends of the readswere clipped.
The fragment length parameterwas set to 100 baseswith a standardde-
viation of 100 bases. Based on these alignments the distribution of the
reads across genomic features was assessed. Isoform expression was
quantiﬁed using the RSEM algorithm (R statistics package rsem) [23].
MicroRNA sequencing reads were aligned to the genome and
quantiﬁed using ncPro-seq (http://www.ncbi.nlm.nih.gov/pubmed/
23044543).
2.5. TaqMan analysis
Messenger RNA quantiﬁcation was performed by transcribing 1.5 μg
mRNA into cDNA using the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Rotkreuz, Switzerland) according to the
manufacturer's recommendations. cDNA samples were diluted 1:5
and subsequently used in real-time PCR analyses (RT-PCR) by mixing
2 μl of cDNA and 8 μl of RT-PCR Universal Fast Master Mix speciﬁc to
the respective cDNA target (TaqMan® Gene Expression Assays, Life-
Technologies). β-actin was used to normalize measurements. miRNAs
were quantiﬁed by transcribing 10 ng of extracted RNA into cDNA
(TaqMan® miRNA Reverse Transcription Kit, Applied Biosystems,
Rotkreuz, Switzerland) using stem-loop reverse transcription primers
speciﬁc for the respective miRNA molecule (TaqMan® MicroRNA As-
says, Life Technologies). RT-PCR analyses were performed using
0.67 μl of cDNA and 9.3 μl of the target-speciﬁc RT-PCR Universal Fast
Master Mix (Applied Biosystems). All measurements were performed
in triplicate.
2.6. Statistics
Generalized Linear Models (GLM) were used for statistical analysis
comparing themRNA andmiRNA expression values across the different
treatment conditions after NGS sequencing. One-sample t-tests were
performed to compare the effects of CDCA on the expression of miRNAs
versus DMSO as measured in TaqMan analysis. MiRNAs and mRNAs
were correlated by Pearson's correlation analyses. Correlation diagrams
were obtained using the “corrplot” library of the R-project, ofmRNA and
miRNA expression levels in both CDCA and DMSO treated cell lines, re-
spectively. The statistical packages SPSS 22 and Graphpad Prism version
5 were used for statistical analyses. p-Valuesb 0.05 were considered
signiﬁcant.
3. Results
3.1. Effect of CDCA on genes involved in bile acid synthesis and transport,
lipid, retinol and estradiol metabolism in hepatocytes
PHHs were treated with CDCA or DMSO (empty vehicle) for either
24 or 48 h to study the effect on the mRNA and miRNA expression pro-
ﬁle. Changes in the expression of mRNAs were in general more pro-
nounced after 48 h, and these results are therefore speciﬁcally
discussed in the following section. Expression of 738 genes was signiﬁ-
cantly decreased and expression of 1566 genes was signiﬁcantly in-
creased (False Discovery Rate (FDR) in both cases ≤46%) after 48 h of
CDCA treatment. When considering a FDR up to 30%, expression of
432 genes was signiﬁcantly increased and expression of 1011 genes
was signiﬁcantly decreased in a BA-dependent manner. Gene enrich-
ment analysis using the bioinformatics tool Metacore™ (Thomson
Reuters) revealed that genes with altered expression in response to
CDCA belong primarily to gene networks involved in BA and lipid trans-
port and metabolism, as well as estradiol and retinol metabolism (Fig.
1). As expected, CDCA increased expression of FXR-inducible genes
such as ABCB11 (BSEP), FGF19, NR0B2 (SHP) or SLC51A and SLC51B
(OSTα, OSTβ) (Table 2).
Genes involved in the regulation of lipid homeostasis that showed
altered expression in response to CDCA included several members of
the apolipoprotein (APO) and fatty acid- binding protein (FABP) family,
SLC27A2 and STARD3, as well as genes involved in cholesterol, lipid and
fatty acid (FA) synthesis andmetabolism, such as CPT1A,HMGCS2, FASN,
ACAT1 and PCSK9 (Table 3).Within signaling pathways inﬂuencing lipid
homeostasis, LDLR, PRKCA1, PPARδ, AGPAT2 and SREBF2were affected by
CDCA. However, nuclear receptors known to control both BA and lipid
homeostasis, e.g., FXR and LXR, were not signiﬁcantly changed in their
expression.
3.2. Effect of CDCA on the expression of drug-metabolizing enzymes
As shown in Table 2, CDCAmodulated the expression of many genes
involved in drug transport and phase I and II drugmetabolism. Amongst
drug-metabolizing cytochrome P450 enzymes, the expression of
CYP2E1, CYP1A1, CYP1A2, CYP2C8, and CYP3A4 was signiﬁcantly de-
creased by CDCA. Amongst phase II enzymes, members of the UDP-
glucuronosyl-transferase (UGT) and sulfotransferase (SULT) families
in particular showed altered expression in response to CDCA. Speciﬁcal-
ly, expression of UGT1A6, 1A7 and 1A9, SULT1E1 and SULT1B1 was
decreased and expression of UGT1A1, 2A8 and 2B10, and SULT1C2 was
increased by CDCA. Transcription factors that regulate drugmetabolism
and excretion, such as the aryl hydrocarbon receptor (AhR), constitutive
androstane receptor (CAR) or peroxisome proliferator-activated recep-
tor γ (PPARγ) also showed altered expression in response to CDCA
(Table 2).
Table 4
Effect of CDCA on the expression of miRNAs in primary human hepatocytes after 48 h.
miRNA⁎ log2 ratio Fold change p-Value FDR
Bile acid dependently up-regulated miRNAs
hsa-mir-552 1.588 3.006 0.0073 0.126
hsa-mir-1260a 1.243 2.367 b0.0001 0.002
hsa-mir-149 1.207 2.309 0.0052 0.115
hsa-mir-1260b 1.186 2.275 b0.0001 0.004
hsa-mir-3651 1.129 2.187 0.0032 0.115
hsa-mir-4485 0.9179 1.889 0.0038 0.115
hsa-mir-3607 0.8542 1.808 0.0043 0.115
hsa-mir-505 0.8398 1.79 0.0035 0.115
hsa-mir-6723 0.7282 1.657 0.0052 0.115
hsa-mir-15b 0.7139 1.64 0.0036 0.115
hsa-mir-328 0.7 1.625 0.0081 0.133
hsa-mir-92a-2 0.6913 1.615 0.0091 0.133
hsa-mir-204 0.5362 1.45 0.0092 0.133
hsa-mir-885 0.4937 1.408 0.0097 0.133
Bile acid dependently down-regulated miRNAs
hsa-mir-34a −0.44 0.737 0.0087 0.133
hsa-mir-30a −0.5096 0.702 0.0055 0.116
hsa-mir-98 −0.6309 0.646 0.0062 0.122
hsa-mir-5590 −0.8854 0.541 0.0036 0.115
hsa-mir-2355 −0.9401 0.521 b0.0001 0.004
hsa-mir-190a −1.1 0.467 0.0022 0.115
hsa-mir-190b −1.266 0.416 0.0096 0.133
hsa-mir-2467 −1.421 0.373 0.0038 0.115
hsa-mir-2114 −1.653 0.318 0.005 0.115
hsa-mir-452 −1.847 0.278 b0.0001 0.002
hsa-mir-486 −2.285 0.205 0.0047 0.115
hsa-mir-486-2 −2.287 0.205 0.0048 0.115
hsa-mir-451b −2.461 0.182 0.0069 0.125
hsa-mir-451a −2.461 0.182 0.0069 0.125
hsa-mir-6503 −2.9 0.134 0.0009 0.073
⁎ Shown are all CDCA dependently modulated microRNAs with a FDR ≤ 0.133 and a
p-value b 0.01.
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3.3. The impact of CDCA on themiRNA expression proﬁle in primary human
hepatocytes
Whereas only few changes in themiRNA proﬁle were observed after
24 h' treatment of PHHs with CDCA, expression of 52miRNAmolecules
was signiﬁcantly increased and that of 29 miRNAs was signiﬁcantly de-
creased after CDCA treatment for 48 h, as shown in Table 4 (FDR b 0.133,
p b 0.01). Results were conﬁrmed by TaqMan analysis remeasuring and
conﬁrming the CDCA dependent downregulation of 3microRNAs (miR-
6503, miR-486 and miR-223) in three separate hepatocyte batches.
ThesemicroRNAs belong to the group ofmiRNAmoleculesmost strong-
ly affected by CDCA, thus, allowing a conﬁrmatory trend determination
in expression by TaqMan analyses. Other microRNAs affected by CDCA
included miR-552, miR-149, and miR-886 (increased) and miR-34a,
miR-30a, miR-452, miR-486 and miR 190a and 190b (decreased). Figs.
2 and 3 illustrate the CDCA-dependent miRNA proﬁle as a volcano plot
and heatmap, respectively. The heatmap integrated cluster analysis
shows considerable interindividual variability in the miRNA expression
proﬁle following CDCA treatment.
3.4. Correlation of CDCA-induced changes in miRNA levels with mRNA
expression
To evaluate the extent to which miRNAs modulated by CDCA could
inﬂuence the expression of genes involved in BA synthesis, transport
and metabolism, Pearson's correlation analyses were performed. Only
those miRNAs (shown in Table 4) that were predicted to bind to at
least three mRNAs contained in the gene cluster regulating BA
homeostasis (Table 2), lipidmetabolism (Table 3) and drugmetabolism
(Table 2) were included in the correlation analyses. Binding of miRNAs
was predicted using the bioinformatics tool mirDIP (http://ophid.
utoronto.ca/mirDIP) [24]. As shown in Fig. 4 a distinct cluster of
mRNAs consisting of ABCG5 and ABCG8, SLC22A7, NR0B2, SLC51B,
SLC10A1, CYP3A4 and FGF19 is inversely associated with the expression
of miR-34a upon CDCA treatment. The same gene cluster appears to be
strongly positively correlated with miRNAs −885, −15b and −505,
leading to the hypothesis that miRNA and mRNA clusters may be regu-
lated by common transcriptional pathways. As demonstrated in Fig. 5,
especiallymicroRNA-1260a shows strong inverse correlationswith sev-
eral important genes involved in lipid homeostasis, including AGPAT2,
S1PR2, CPT1A, APOM, AKR1C1 and LDLR upon CDCA treatment pointing
to an inhibitory effect of miR-1260a on the expression of this gene bat-
tery. In contrast to miR-1260a, miRNA-98 that is strongly inversely cor-
related with a gene battery including amongst others NPC1L1, HMGCS2,
AGPAT2, FASN, STARD3 and S1PR2l, loses many of those inverse associa-
tions upon CDCA treatment. This observation points to a less strong reg-
ulatory impact ofmiR-98 on the lipid gene network upon higher hepatic
BA concentrations. Fig. 6 demonstrates the correlation behavior of
mRNAs belonging to the drug metabolism network and distinct
microRNAs. Interestingly miRNA-1260 comes here to the fore again,
now with two family members -1260a and -1260b, showing both
strong positive correlations with the drug metabolizing enzymes
SULT1E1, CYP1A1 and CYP1A2 and CYP2E1. >Less strong but still relevant
positive associations in gene expression are also observed with the UGT
family members UGT2A3, UGT1A7, UGT1A8 and CYP2C8. This observa-
tion suggests a connection between miR-1260 expression and the
Fig. 2. Effect of CDCA on the global miRNA proﬁle in ﬁve batches of primary human hepatocytes. Dots represent the average fold-change of miRNAs shown as log2 values (x-axis) and
corresponding p-values represented as –log10 values (y-axis) when comparing CDCA and empty vehicle (DMSO) treated cells. Red: miRNAs with p-values b0.01. Yellow: miRNAs with
p-values b0.05. Green: miRNAs with p-values N0.05. Labeled miRNAs represent molecules that showed a ≥ 2fold increase or decrease.
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expression of thementioned genes, either through a common regulato-
ry element of via indirect signaling pathways involving miRNA-1260 as
regulatory compound with impact on e.g. an inhibitory transcription
factor regulating the mentioned gene battery.
4. Discussion
We systematically investigated the effect of CDCA on themRNAome
and miRNAome in human hepatocytes. Using CDCA as a model sub-
stance we demonstrate that BAs have the ability to profoundly change
the transcriptional pattern of gene networks involved in BA and lipid
homeostasis, as well as drug metabolism and disposition. These results
together with our observation that distinct microRNAs appear to be bile
acid dependently changed in expression provide important novel
insights into the regulatory mechanisms behind systematic effects of
BAs that are of both liver therapeutic and toxicological relevance.
CDCA had both enhancing and suppressing effects on the expres-
sion of miRNAs, with the majority of the miRNA molecules having
decreased levels under CDCA treatment. Importantly, we show
that CDCA modulates the expression of distinct miRNAs that appear
to be connected to the expression of gene clusters within the bile
acid, lipid and drug homeostasis associated gene networks.
MicroRNA-34a is CDCA dependently and strongly inversely corre-
lated with key genes involved in BA homeostasis including FGF19,
NR0B2 (SHP), OSTα/β, ABCG5/ABCG8, and SLC22A7. This ﬁnding
suggests a key role of miR-34a in the autoregulation of bile acid ho-
meostasis. We observed a strong downregulation of miR-34a, which
is well in line with results published by Castro et al. (2013), showing
a suppressive effect of ursodeoxycholic acid in patients suffering
from NAFLD [25]. The suppressive effect of CDCA on miR-34a ex-
pression suggests also consequences for NAFLD development, and
the regulation of energy homeostasis and cancer related pathways.
MicroRNA-34a has been shown to SIRT-dependently regulate
brown fat formation. The observed upregulation of serum miR-34a
in NAFLD patients underlines the importance of miR-34a in meta-
bolic diseases [26]. MiRNA-34a has been studied in the context of
cancer development and tumor growth. Associations with disease
development, prognosis and severity have been described for blad-
der, breast, liver and colon cancer as well as lymphoma [27–30]. Be-
sides miR-34a, we detected a distinct microRNA cluster, composed
of miR-885, miR-505 and miR-15b, to be CDCA dependently modu-
lated in expression. These microRNAs were signiﬁcantly upregulat-
ed and showed, in contrast to miR-34a - a positive correlation with
the group of genes inversely associated with the expression of miR-
34a. It is conceivable that these three miRNAs and the associated BA
gene cluster are co-regulated by a common transcriptional pathway
that is activated by CDCA. MiRNA-885 has been shown to play a role
in the pathogenesis of different cancer types [31,32] and has also
been discussed as a potential serum marker for the detection of
ongoing liver pathologies [33]. MiR-15b has been shown to be up-
Fig. 3.Heat map showing CDCA-induced changes in miRNA proﬁle clustering in ﬁve batches of primary human hepatocytes. MiRNAs with changes of at least 50% and p-values b0.05 are
shown. Red: increased miRNAs. Green: decreased miRNAs.
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regulated in NAFLD, and thus, has been suggested to play a role in
the pathogenesis of this disease [34]. MicroRNA-505-3p is discussed
as putative biomarker for primary biliary cirrhosis [35].
CDCA strongly affected genes involved in lipid homeostasis, includ-
ing FGF2, FGFR2, HMGCS2, FABP and APO family members. As potent
ligands for FXR, CDCA and other BAs regulate genes involved in
Fig. 4. Pearson's correlation analyses on mRNA and miRNA expression levels taking genes from the BA gene cluster into consideration. DMSO treatment (A), CDCA treatment (B).
MicroRNAs with predicted binding sites in at least three target genes within the bile acid (BA) gene cluster and signiﬁcantly up- analyses on mRNA and miRNA expression levels
taking genes from the BA gene cluster into consideration. DMSO treatment (A), CDCA treatment (B). MicroRNAs with predicted binding sites in at least three target genes within the
bile acid (BA) gene cluster and signiﬁcantly up– or downregulated (FDR ≤ 0.133) were included. Shown are BA mRNA targets that were signiﬁcantly up or downregulated by CDCA
(FDR b 0.46). Blue, positive correlation; red, inverse correlation. A distinct gene cluster composed of important BA homeostasis regulating genes, comprising SLC51A, CYP3A4, SLC22A7,
NR0B2, ABCG5/8, SLC51B, FGF19 and SLC10A1 appears to be strongly inversely correlated with miRNA-34a and positively correlated with the microRNAs miR-885, miR-15b, and miR-
505 upon CDCA treatment (highlighted in green).
Fig. 5. Pearson's correlation analyses on mRNA and miRNA expression levels taking genes from the lipid gene cluster into consideration. DMSO treatment (A), CDCA treatment (B).
Analyses included miRNAs signiﬁcantly up- or downregulated and with predicted binding sites in at least three target genes within the lipid gene cluster. Shown are lipid cluster
mRNA targets signiﬁcantly up- or downregulated. Blue, positive correlation; red, inverse correlation. A distinct gene cluster composed of important lipid homeostasis regulating genes,
such as S1PR2, CPT1A, APOM, AKR1C1 and LDLR is strongly inversely correlated with the expression of miR-1260a upon CDCA treatment (highlighted in green).
53R. Krattinger et al. / Life Sciences 156 (2016) 47–56
cholesterol, FA, and lipid metabolism, either by direct transcriptional
activation or by FGF-dependent hormonal signaling. In vivo studies
performed in mice have shown that orally administered BAs lead to
a positive effect on body weight [36] and lower the risk for NAFLD
under high-fat diet conditions [2]. Our results support the notion
that BAs modulate the expression pattern of genes involved in lipid
synthesis, transport and metabolism, which could contribute to the
lipid lowering properties repeatedly observed with BAs. In this con-
text we would like to highlight the enhancement of miR-1260 ex-
pression upon CDCA treatment, which was associated with a strong
parallel expression of genes involved in xenobiotica metabolism
(CYP2E1, CYP1A1, CYP1A2) and an inverse expression of important
genes involved in lipid homeostasis (i.e. CPT1A, APOM, LDLR). This
ﬁnding points to a putative coregulatory element regulating the ex-
pression of miR-1260 and the mentioned drug gene group and a
role of this microRNA as regulatory element in lipid metabolism.
MicroRNA-1260 has been recently described as putative biomarker
for paclitaxel-induced apoptosis in HCC cells [37]. Our systematic
analysis of genes involved in drug metabolism and transport show,
that many genes belonging to phase I (CYP1A members, CYP2E1,
CYP2C8), phase II (several genes of the UGT and SULT family) and
phase III (SLC22A1, SLC22A7) are signiﬁcantly modulated by CDCA.
This observation allows the speculation that bile acid derivates may
have the potential to induce drug-drug interactions with other com-
pounds through the modulation of DM gene expression. The impor-
tance of our ﬁndings with regard to a relevant interplay of BAs and
DMEs is further underlined by the fact that distinct and relevant
drug-drug interactions with BAs have been earlier described in
other studies. This comprises amongst others the interaction be-
tween the immunosuppressant Ciclosporine A and bile acids.
Ciclosporine A has been demonstrated to lead to a signiﬁcant accu-
mulation of bile acids and the development of a cholestatic feature
in liver derived HepaRG cells [38]. Another important example com-
prises the interaction of the calcium channel blocker nitrendipine
and CDCA. Sasaki and co-workers demonstrated that CDCA and
UDCA are able to inhibit nitrendipine absorption by 50% and thus
to decrease plasma concentrations of nitrendipine to a clinically
relevant extent in healthy individuals [39].
Because the ﬁve batches of PHHs were obtained from patients
resected for liver metastases that were incurred through different ma-
lignant tumors such as colon or kidney cancer, it cannot be excluded
that the underlying pathologies or the existence of genetic polymor-
phisms within the discussed gene clusters or in genes coding for key
transcription factors could induce an additional variance in gene expres-
sion.We speciﬁcally concentrated on the question to what extent CDCA
is able to change the microRNA proﬁle, as also optimally measurable in
the chosen time frame of 48 h. Itwould be interesting to further study in
future studies how and to what extent other epigenetic regulatory
mechanisms, such as e.g. methylation or histone acetylation, are inﬂu-
enced by CDCA. Correlation analyses were done at the miRNA/mRNA
level. Because the regulatory effect of miRNAs is often only observed
at the protein level, we cannot exclude the possibility that the miRNAs
have additional effects on targets that were not detected by assessment
of mRNA levels alone.
We conclude that the expression of the human miRNAome and
mRNAome in PHHs are signiﬁcantly modulated by the bile acid
CDCA, with relevant consequences for the functionality of gene
networks involved in bile acid, lipid and drug metabolism.
CDCA-induced regulation by miRNAs may exert downstream
effects on genes within functionally important networks. Our
ﬁndings give important novel insights into the ability of BA deri-
vates to induce relevant changes in gene networks relevant for
BA compound safety and metabolic disease development such as
obesity and NALFD.
Fig. 6. Pearson's correlation analyses onmRNAandmiRNA expression levels taking genes from theDMgene cluster into consideration.DMSO treatment (A), CDCA treatment (B). Analyses
were performed including thosemiRNAs thatwere signiﬁcantly up- or downregulated and for which binding sites in at least three target genes within the drug transport andmetabolism
(DM) gene cluster were predicted. Shown are DMmRNA targets that were signiﬁcantly up- or downregulated. Blue, positive correlation; red, inverse correlation. A distinct gene battery,
composed of important genes encoding drug metabolizing enzymes, including SULT1E1, CYP1A2, CYP1A1 and CYP2E1 and to a less extent several UGT family members and CYP2C8, is
positively correlated with the expression of miR-1260a and miR-1260b upon CDCA treatment (highlighted in green).
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Krattinger R, Boström A, Schiöth HB, Thasler WE, Mwinyi J,
Kullak-Ublick GA. microRNA-192 suppresses the expression of the
farnesoid X receptor. Am J Physiol Gastrointest Liver Physiol
310: G1044 –G1051, 2016. First published April 14, 2016;
doi:10.1152/ajpgi.00297.2015.—Farnesoid X receptor (FXR,
NR1H4) plays an important role in the regulation of bile acid homeo-
stasis in liver and intestine and may exert protective effects against
certain forms of cancer such as colon carcinoma. However, the role of
FXR in cell growth regulation, apoptosis, and carcinogenesis is still
controversial. Similar to FXR, microRNA-192 (miR-192) is mainly
expressed in the liver and colon and plays an important role in the
pathogenesis of colon carcinoma. In this study, we investigated the
extent to which FXR is regulated by miR-192. Two in silico-predicted
binding sites for miR-192-3p within the NR1H4-3= untranslated re-
gion (UTR) were examined in vitro by luciferase reporter assays.
Wild-type and mutated forms of the NR1H4-3=UTR were subcloned
into a pmirGLO vector and cotransfected into Huh-7 cells with
miR-192-3p. To study the effects of miR-192 on the expression of
FXR, FXR target genes and cell proliferation, Huh-7 and Caco-2 cells
were transfected with miR-192-5p and -3p mimics or antagomirs. In
addition, the correlation between FXR and miR-192 expression was
studied by linear regression analyses in colonic adenocarcinoma tissue
from 27 patients. MiR-192-3p bound specifically to the NR1H4-
3=UTR and significantly decreased luciferase activity. Transfection
with miR-192 led to significant decreases in NR1H4 mRNA and
protein levels as well as the mRNA levels of the FXR-inducible bile
acid transporters OST-OST and OATP1B3. Significant inverse
correlations were detected in colonic adenocarcinoma between
NR1H4 mRNA and miR-192-3p expression. In summary, microRNA-
192 suppresses the expression of FXR and FXR target genes in vitro
and in vivo.
miR-192; farnesoid X receptor; bile-acid transporters; drug-induced
liver injury; colonic adenocarcinoma
NUCLEAR FARNESOID X RECEPTOR (FXR, NR1H4) is a ligand-
activated transcription factor that plays a crucial role in the
regulation of bile acid, cholesterol, lipid, and glucose homeo-
stasis. It is mainly expressed in the liver, intestines, kidney, and
adrenal glands (34). FXR regulates key genes involved in
human bile acid synthesis and metabolism, including bile acid
transporters (4). Studies on FXR knockout mice have shown
that FXR exerts hepatoprotective effects. Diminished FXR
expression has been linked to an increase in inflammatory
responses and neoplastic transformation in mice (7, 16).
Mice lacking FXR expression show elevations in serum and
hepatic bile acid levels and a higher incidence of hepato-
(cholangio)cellular carcinoma (12, 33). In mouse intestine,
loss of FXR and subsequent elevations of intestinal bile acid
concentrations lead to earlier mortality caused by increased
tumor progression via promotion of Wnt signaling. FXR
may play a key role in the intestinal defense against poten-
tially toxic bile acids by regulating their transport, detoxi-
fication, and neosynthesis (8, 23). Decreased FXR expression
levels in human colon cancer tissue compared with nonneo-
plastic tissue are associated with adverse clinical outcome (15).
In contrast, strongly enhanced FXR expression, leading to
altered expression of FXR-regulated drug uptake transporters,
confers chemoresistance in cancer patients (22). The role of
FXR in cell growth regulation, apoptosis, and carcinogene-
sis is controversially discussed in the literature. An immu-
nohistochemical study, for example, showed preserved or
enhanced FXR protein expression in tumor cell nuclei of
human hepatocellular carcinoma tissue compared with he-
patocyte nuclei of normal and diseased liver (14).
MicroRNAs (miRs) are short noncoding RNA molecules of
18–25 nucleotides in length that repress specific target mRNAs
by degradation or translational repression (2). Two important
liver-specific miRNAs are miR-122, which is estimated to
comprise 70% of the total hepatic miR pool in adults, and
miR-192 (28). The gene encoding hsa-miR-192 is located on
chromosome 11. In addition to expression in the liver, miR-192
is found in the kidneys and gastrointestinal tract (20). Elevated
serum levels of miR-192 have been detected in various liver-
associated diseases, including drug-induced liver injury, non-
alcoholic steatohepatitis, cholangiocarcinoma, and hepatitis
B-related hepatocellular carcinoma and may serve as a bio-
marker (24, 26, 28, 31, 37). Thus several studies have hypoth-
esized that tissue-specific chronic inflammation may trigger
increases in miR-192 expression, as in nonalcoholic steato-
hepatitis (21, 24, 26). Because miR-192 shows an inverse
correlation with the metastatic potential of colon cancer cells,
miR-192 has been suggested to be a predictive biomarker for
the risk of developing liver metastasis in colon carcinoma. In
vivo studies in mice suggest that miR-192 targets B-cell
lymphoma 2 (BCL2), zinc-finger E-box-binding homeobox 2
(ZEB2), and vascular endothelial growth factor A (VEGFA), all
of which are important antiapoptotic and angiogenic regulators
(9). The tumor suppressor protein p53 can act as a transcription
factor within the miR-192 promoter, whereas miR-192 itself
appears to suppress carcinogenesis by promoting p21 accumu-
lation (3, 27). Loss of p53 functions by mutation and conse-
quently decreased expression of miR-192 has been suggested
to be a key step in colon carcinogenesis (3, 11, 25, 29).
Although miR-192 is not considered to be a typically dysregu-
lated microRNA in several studies on hepatocellular carcinoma
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(HCC), Lian et al. (19) showed a significantly suppressed
expression of miR-192 in HCC tissue compared with nontu-
morous tissue. An important role of miR-192 targeting ZEB2
mRNA has also been found in HCC (13). In contrast, certain
forms of cancer, such as cholangiocarcinoma and esophageal
cancer, show increased miR-192 expression during carcino-
genesis (21, 26).
In this study, we investigated to what extent miR-192
modulates the expression of FXR and thereby affects the
expression of FXR target genes in liver and colon cancer-
derived cell lines.
MATERIALS AND METHODS
Bioinformatics. An in silico search for possible miRNA-binding
sites in the 3= untranslated region (UTR) of the NR1H4 gene was
performed by using miRANDA (Memorial Sloan-Kettering Cancer
Center, New York, NY), DIANA-microT-CDS (Biomedical Science
Research Center Alexander Fleming, Athens, Greece) and miRBase
(Faculty of Life Science, University of Manchester, Manchester, UK).
mRNA and miR expression data from 27 colonic adenocarcinoma
tissue samples [E-GEOD-29623, Affymetrix GeneChip Humane Ge-
nome U133 Plus 2.0 and NIH TaqMan microRNA Array v.2 (5)] were
retrieved from the openly accessible platform ArrayExpress (EMBL-
European Bioinformatics Institute, Wellcome Trust Genome Campus,
Hinxton, UK).
Cell culture. The human hepatoma-derived Huh-7 and colon car-
cinoma-derived Caco-2 cell lines (American Type Culture Collection,
Molsheim, France) were cultured in RPMI-1640 and Dulbecco’s
modified Eagle’s medium (Life Technologies, Carlsbad, CA), respec-
tively, supplemented with 10% fetal bovine serum (Sigma-Aldrich, St.
Louis, MO), 100 U/ml penicillin, and 100 g/ml streptomycin (Invit-
rogen, Carlsbad, CA). Primary human hepatocytes (PHHs) obtained
from three patients suffering from primary or secondary liver carci-
noma (ethical approval by the Local Ethical committee of the Uni-
versity of Munich, Germany, and the Ethics Committee of the Canton
of Zurich, Switzerland) were isolated from the cancer-adjacent normal
tissue and cultured as described (17). PHHs were kept in maintenance
medium including ultraglutamine for 5 h before further procedures.
Cell cultures were incubated at 37°C in a humidified atmosphere with
5% CO2.
Transient transfection with miR-192. To investigate the effect of
miR-192 on NR1H4 mRNA and protein expression, Huh-7 and
Caco-2 cells were seeded in 12-well plates (8104 and 4105
cells/ml, respectively). After 24 h, cells were transfected with 100 nM
hsa-mirVANA miRNA mimics or anti-miR miRNA inhibitors (hsa-
miR-192-3p/-5p and corresponding negative controls, Life Technol-
ogies) by using Lipofectamine RNAiMax diluted in Opti-MEM I
(both purchased from Invitrogen) at a final concentration of 3 mM.
Hsa-miR-1 and its known suppressive effect on twinfilin-1 (TWF-1)
expression were used as a positive control. After 4 h of incubation, the
transfection medium was replaced with fresh complete growth me-
dium. At 24, 48, and 72 h after transfection, total mRNA and protein
were isolated by use of TRIzol reagent (Life Technologies) and RIPA
buffer [50 mM Tris·HCl pH 8, 150 mM NaCl, 1% Nonidet P-40, 0.5%
sodium deoxycholate (all from Sigma-Aldrich), 1 mM EDTA (Phar-
macia Biotech, Uppsala, Sweden), and 0.1% SDS and 10% glycerol
(both from Sigma-Aldrich)], respectively. FXR mRNA and protein
were quantified in three independently performed experiments.
To examine miR-192-dependent expression of FXR target genes,
Huh-7 cells were treated with 50 M chenodeoxycholic acid (CDCA)
(Sigma-Aldrich) for 24 h. Data obtained were merged from four
experiments, and the three most representative values were averaged.
To prove that miR-192 mimics control the expression of FXR target
genes through FXR regulation, 100 nM FXR small interfering RNA
(siRNA) or corresponding negative control (Life Technologies) were
transfected simultaneously with the miRNA mimics for 48 h.
Reverse transcription and quantitative real-time PCR. Extracted
RNA (1.5 g) was transcribed into cDNA by a High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Waltham, MA) ac-
cording to the manufacturer’s protocol. A total of 2 l of 1:5 diluted
cDNA was mixed with 8 l RT-PCR Universal Fast Master Mix
(Applied Biosystems) including specific primers (TaqMan Gene Ex-
pression Assays NR1H4, SLCO1B3, SLC51A, and SLC51B; Life
Technologies) and subjected to real-time PCR. -Actin was used as an
internal control. To measure miR expression, 10 ng of extracted RNA
was reverse transcribed into cDNA by using a TaqMan miRNA
Reverse Transcription Kit (Applied Biosystems) and specific stem-
loop reverse transcription primers (TaqMan MicroRNA Assays hsa-
miR-192-3p and hsa-miR-192-5p; Life Technologies). RT-PCR was
performed by using 0.67 l cDNA and 9.3 l RT-PCR Universal Fast
Master Mix (Applied Biosystems) including primers. U6snRNA was
used as an internal control. Mean miR expression in three passages of
cells were analyzed per cell line. All measurements were performed in
triplicate.
Western blot analysis. Protein samples (17–30 g) were diluted 1:5
with loading buffer, denatured, and separated by 8% SDS-polyacryl-
amide gel electrophoresis. The separated proteins were transferred to
polyvinylidene fluoride membranes and preincubated for 1 h in
blocking buffer and then for 16 h with the primary antibodies
(anti-FXR, Santa Cruz Biotechnology, Dallas, TX; anti--actin, Ab-
cam, Cambridge, UK) at 4°C. After four washing steps, the mem-
branes were incubated with a horseradish peroxidase-conjugated sec-
ondary antibody (goat-anti-rabbit, Thermo Scientific, Waltham, MA)
for 1 h at room temperature. Protein bands were visualized with
SuperSignal West Femto Maximum Sensitivity Substrate (Thermo
Scientific) and Fusion FX7 (Vilber Lourmat, Eberhardzell, Germany).
-Actin was used as a housekeeping gene.
Transient cotransfection with miR-192-3p (miR-192*) and NR1H4
3=UTR plasmid constructs and luciferase reporter assays. To examine
the NR1H4 3=UTR as a target of miR-192-3p in vitro, luciferase
assays were performed with a pmirGLO Dual-Luciferase miRNA
Target Expression Vector (Promega, Fitchburg, WI), containing both
the coding sequences of firefly luciferase and Renilla luciferase
(internal control). The NR1H4 3=UTR (accession number
NG_029843.1) was cloned into the pmiRGLO vector system by using
specific primers (Table 1). Plasmids were verified by Sanger sequenc-
ing. Huh-7 cells were seeded in 48-well plates (1.6105 cells/ml).
After 24 h, the cells were transfected with 50 nM hsa-mirVANA
miRNA mimics or a negative control (hsa-miR-192-3p, Negative
Control no. 1; Life Technologies) and 100 ng/well of plasmid DNA
with use of Lipofectamine 2000 (Invitrogen). The activities of firefly
and Renilla luciferases were measured at 24 h after cotransfection
using the Dual-Luciferase Reporter 1000 Assay System (Promega)
according to the manufacturer’s protocol. Hsa-miR-21-5p and its
effect on the miR-21 target sequence were used as a positive control.
Analysis was performed using the GloMax Multi Detection System
(Promega). An empty pmirGLO vector was used as a background
control. QuikChange Multi Site-Directed Mutagenesis and
QuikChange II XL Site-Directed Mutagenesis Kits (Agilent Technol-
ogies, Santa Clara, CA) were used to introduce mutations into the
miR-192-3p-binding sites using specific primers (Table 1). Three
independent luciferase reporter assays were performed including
wild-type and mutated target sequences.
Cell proliferation and invasion assays. Cell proliferation was
determined by using the alamarBlue (Thermo Scientific) cell viability
reagent according to the manufacturer’s instructions. Briefly, Huh-7
and Caco-2 cells were seeded in 96-well plates (7.5104 and 2105
cells/ml, respectively). After 24 h, cells were transfected with 100 nM
miR-192 mimics, FXR siRNA, or the corresponding negative con-
trols. After 48, 72, and 96 h 10 l of alamarBlue was added to each
well and cells were incubated for 4 h at 37°C. The absorbance was
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determined at 560/600 nm by using the GloMax Multi Detection
System.
Cell invasion was determined with extracellular matrix-coated
invasion chambers (QCM 24-well cell invasion assay, Millipore,
Billerica, MA) according to the manufacturer’s instructions. Huh-7
and Caco-2 cells were harvested and resuspended in serum-free
medium after pretreatment for 48 h with miR-192 mimics or negative
control (cell density for transfection: 1  105 and 4  105 cells/ml,
respectively). Then, 1  105 cells were plated into the invasion
chamber, whereas the bottom well of the chamber contained 500 l of
the corresponding medium supplemented with 10% FBS. After 48 h
of incubation, the invaded cells on the underside of the membrane
were detached, lysed, and stained with CyQuant GR Dye (Millipore).
Fluorescence was measured by use of a 490/510–570 filter set and
GloMax Multi Detection System.
Statistical analysis. Paired one-sample t-tests were performed to
compare the effects of miR-192 mimics, antagomirs, FXR siRNA and
the corresponding negative controls on FXR mRNA/protein expres-
sion levels and on cell proliferation/invasion. Luciferase activities
were compared between miR-192-3p- and mock-transfected cells by
one-way analysis of variance. All data obtained from transfection
experiments were compared with negative control mimics or inhibi-
tors, in which expression levels in mock-transfected cells were defined
as 1 (except for cell proliferation assays, where values were normal-
ized to the 48-h time point of a particular condition). In general, the
negative controls were not expected to bind to the NR1H4 3=UTR or
to block the activity of endogenously expressed miR-192. Only
experiments with verified positive controls were included in statistical
analyses. The association between FXR and miR-192 expression
levels was investigated in 27 colonic adenocarcinoma tissue samples
by linear regression analyses excluding subjects that had undergone
chemotherapy [E-GEOD-29623 (5)]. Values are shown as averages
standard deviation. A P value of less than 0.05 was considered to be
statistically significant. Statistical analyses were performed with R
Software (version 2.15.2) and GraphPad Prism (version 5.04).
RESULTS
The mature forms of pre-miR-192 derived from the 5= and 3=
strands of the precursor are detectable in Huh-7 and Caco-2
cells. The online database miRBase lists two mature sequences
for the human miRNA precursor pre-miR-192, miR-192-5p,
and miR-192-3p. Quantitative measurement of the endogenous
expression levels showed the presence of both strands at
considerable amounts in Huh-7, PHH, and Caco-2 cells. MiR-
#-3p was expressed 10-fold less in Huh-7 cells, 32-fold less in
Caco-2 cells, and 39-fold less in PHH cells compared with
miR-#-5p. Furthermore, miR-192-3p showed a 9- to 10-fold
higher expression in Caco-2 cells than in the hepatoma cell line
or the primary human hepatocytes (data not shown).
Confirmation of the NR1H4 3=UTR as a target of miR-
192-3p by luciferase reporter assays. The software tools
miRANDA and DIANA-microT-CDS predicted binding of
miR-192-3p to NR1H4 transcript positions 199–227 and 324–
A
B
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| | | | | | | | | |
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Fig. 1. A: predicted binding sites for the seed sequence of miR-192-3p in the
3=UTR of NR1H4 mRNA using the bioinformatic tool miRANDA (www.
microrna.org). B: relative reporter gene activities at 24 h after cotransfection of
Huh-7 cells with the wild-type NR1H4-3=UTR target clone or mutated NR1H4-
3=UTR target clone. The miR target clone control vector was used for
normalization. Experiments were performed as triplicates and repeated 3 times.
**P  0.01; ns, not significant.
Table 1. Primer sequences used for subcloning and mutagenesis
Oligonucleotide Sequence (5=–3=) Purpose
FXR_3UTR_FW aggagctctggggattacaggggagg Subcloning of NR1H4 3= end
into pmirGlo
FXR_3UTR_RV aggtcgacgccaagattgaatacaactct Subcloning of NR1H4 3= end
into pmirGlo
FXRmut_miR192*_FW1 ggaatcctgcattctagtcgccgagccctgtttgcctaattaaattg Multisite-directed
mutagenesis
FXRmut_miR192*_FW2 gagttgtattcaatctggccgtcgacctaatcccgcggc Multisite-directed
mutagenesis
FXRwt_miR192*_FW gagttgtattcaatcttggcagtcgacctaatcccgcggc Site-directed mutagenesis
FXRwt_miR192*_RV gccgcgggattaggtcgactgccaagattgaatacaactc Site-directed mutagenesis
Recognition sites for the restriction enzymes are underlined in the primers used for subcloning. In silico-predicted binding sites for hsa-miR-192-3p are
underlined in the mutagenesis primers, whereas mutations inserted into these sites are indicated in bold. FXRwt_miR192* primers were used to optimize the
second binding site for miR-192-3p.
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352 (position relative to translational stop codon,
NG_029843.1, Fig. 1A). No binding site within the NR1H4
3=UTR was predicted for miR-192-5p. Cotransfection of
miR-192-3p mimics and the NR1H4 3=UTR target sequence
into Huh-7 cells resulted in a 30% decrease in luciferase
activity compared with the empty vector control (P  0.01).
In contrast, luciferase activity remained unaffected by
cotransfection of the NR1H4 3=UTR target sequence carry-
ing the miR-192 binding sites in the mutated form compared
with the wild-type construct (Fig. 1B), indicating a negative
interaction of miR-192-3p with the predicted binding sites
in the NR1H4 3=UTR.
MiR-192 attenuates endogenous NR1H4 mRNA levels in
Huh-7 and Caco-2 cells. To investigate the effect of miR-192
on endogenous FXR expression levels, Caco-2 and Huh-7 cells
were transfected with 100 nM miR-192-3p or -5p mimics for
24 or 48 h. As shown in Fig. 2A, NR1H4 mRNA levels were
repressed to 75 and 65% by miR-192-3p and -5p mimics,
respectively, in Huh-7 cells (P  0.05). In Caco-2 cells, a
decrease by 15 and 28% in NR1H4 mRNA expression was
detected after transfection with miR-192-3p and -5p mimics for
24 h (P  0.05). To examine whether transfection of an
antagomir could reverse the endogenous miR-192-dependent
inhibitory effect on FXR expression, Caco-2 and Huh-7 cells
were transfected with 100 nM anti-miR-192 inhibitors for 24 or
48 h, respectively. As shown in Fig. 2B, NR1H4 mRNA levels
were increased significantly by anti-miR-192-3p inhibitors in
Caco-2 cells as well as anti-miR-192-5p inhibitors in Huh-7
cells compared with the anti-miR miRNA inhibitor negative
control (P  0.05). Thus the miR-192-dependent effect on
FXR regulation appeared to be stronger in Huh-7 cells com-
pared with Caco-2 cells.
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MiR-192 suppresses FXR protein translation in Huh-7 and
Caco-2 cells. Consistent with the miRNA-dependent effects on
NR1H4 mRNA expression, a 63% decrease in FXR protein
expression was seen after transfection with miR-192-3p mimic
in Huh-7 cells (P  0.05). Weaker downregulation by 14%
was observed after transfection of miR-192-5p. A decrease by
14 and 43% in FXR protein expression was observed in Caco-2
cells after transfection with miR-192-3p and -5p, respectively
(Fig. 3A). As shown in Fig. 3B, the endogenous miR-192-
dependent suppressive effect on FXR protein expression was
reversed upon transfection with anti-miR-192-3p or -5p inhib-
itors. In Huh-7 cells, an increase in FXR protein levels was not
seen following transfection of the miR-192-3p antagomir,
which could be explained by the lower expression of the 3= in
relation to the 5= strand in Huh-7 compared with Caco-2 cells.
MiR-192 suppresses the expression of key FXR target genes.
The bile acid transporters organic-anion transporting polypep-
tide 1B3 (OATP1B3, SLCO1B3) and organic solute transport-
ers / (OST alpha/beta, SLC51A/B) were chosen as model
genes to examine the effect of miR-192 on FXR-regulated
expression of transport proteins. Huh-7 cells were transfected
with 100 nM miR-192-3p or -5p for 48 h. At 24 h after
transfection, cells were treated with 50 M CDCA for 24 h to
activate FXR and compared with the miRNA mimic negative
control. As shown in Fig. 4, SLCO1B3, SLC51A, and SLC51B
mRNA levels were decreased by either one or both strands of
miR-192, suggesting a reduction of gene transcription second-
ary to reduced expression of the transcriptional activator FXR.
This was confirmed by simultaneous FXR knockdown and
miRNA transfection experiment (data not shown).
Linear regression analyses reveal an inverse association
between the expression levels of miR-192 and FXR in colonic
adenocarcinoma. To investigate whether the in vitro effects of
miR-192 on FXR expression were reproducible in vivo, we
analyzed 27 tissue samples from chemotherapy-untreated pa-
tients with primary colonic adenocarcinoma (Table 2). As
shown in Table 3 and Fig. 5, a significant inverse association
in expression was observed for the NR1H4 mRNA transcript
coding for FXR2() and hsa-miR-192-3p. FXR2 isomers
represent the most abundantly expressed FXR protein forms in
colonic tissue, whereas the isomer FXR1 is predominantly
expressed in liver (30). No significant associations were found
for NR1H4 mRNA and hsa-miR-192-5p expression, showing
that the 5= strand does not confer pronounced NR1H4 mRNA
degradation in vivo. These findings support the regulatory
effects of miR-192 on FXR expression in hepatoma and colon
cancer-derived cell lines observed in vitro.
MiR-192 exhibits suppressive effects on proliferation of
Huh-7 and Caco-2 cells. To investigate the functional signif-
icance of the observed miR-192/FXR interaction, we per-
formed cell proliferation assays using alamarBlue. As shown in
Fig. 6, transfection with miR-192-3p mimic significantly re-
duces proliferation of Huh-7 and Caco-2 cells, whereby a
stronger effect could be observed in the hepatoma cell line.
These findings confirm the previously described suppressive
effects of miR-192 on proliferation of the colon cancer cell
lines HT-29, RKO, and HCT116 (27). Knockdown of FXR
expression causes similar antiproliferative effects in Huh-7
cells. In contrast, reduction in FXR expression does not seem
to have any influence on the proliferative potential of Caco-2
cells. By performing cell invasion assays, we saw a trend
toward a suppressive effect for both strands of the miR-192
precursor molecule on cell invasion of Huh-7 cells; however,
the results were not significant (data not shown). In a previous
work, Lian et al. (19) showed that miR-192 could significantly
downregulate cell invasion of Huh-7 cells.
DISCUSSION
The aim of this study was to investigate whether FXR is a
target of miR-dependent, posttranscriptional gene regulation.
Regulation of FXR expression by miR-421 as an oncogenic
miR in biliary tract cancer has already been postulated (36).
Our results show an additional, as yet uncharacterized role of
miR-192 in regulating FXR expression.
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Table 2. Clinical characteristics of 27 patients with primary
colonic adenocarcinoma
Parameters Category N (%)
Gender male 15 (55.6)
female 12 (44.4)
AJCC stage pT1 6 (22.2)
pT2 13 (48.2)
pT3 4 (14.8)
pT4 4 (14.8)
Tumor grade 1 3 (11.1)
2 20 (74.1)
3 4 (14.8)
Treatments chemotherapy-naive 27 (100)
Clinical characteristics of the 27 patients showing primary colonic adeno-
carcinoma who were included into linear regression analysis. AJCC, American
Joint Committee on Cancer.
Table 3. Linear regression analysis of miR-192-3p
expression with FXR2(), FXR1(	), and miR-192-5p
expression in primary colonic adenocarcinoma
Transcript Coefficient Standard Error P Value
FXR2() 	1.57 0.66 2.59E-02
FXR1(	) 1.87 0.70 1.39E-02
hsa-miR-192-5p 0.31 0.14 4.13E-02
Linear regression analysis of hsa-miR-192-3p with the NR1H4 mRNA
transcripts coding for FXR2() and FXR1(	), and miR-192-5p expression
in primary colonic adenocarcinoma tissue obtained from 27 patients. miR-
192-3p inversely correlates with FXR2() expression. Adjusted R2: 0.348.
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Our in vitro experiments elucidated the inhibitory effect of
miR-192 on FXR expression by transfecting colon and liver
cell lines with miR-192 mimics and inhibitors. In the case of
the 3= strand, we found a significant miR-192-dependent in-
hibitory effect on NR1H4/FXR mRNA and protein expression
in Huh-7 cells, whereas in Caco-2 cells only transfection with
the anti-miR-192-3p inhibitor showed a relevant effect. A
possible explanation for the observed weaker inhibitory effect
of the miR-192-3p mimic in Caco-2 cells, compared with that
in Huh-7 cells, may be the more abundant expression of
miR-192 in the colon cell line. The observed miR-192*-
dependent effects on NR1H4 mRNA levels in both cell lines
and our in vivo findings that showed a strong inverse miR-192*
and FXR2() correlation in colonic adenocarcinoma support
our hypothesis of a strong endogenous effect of miR-192 on
FXR expression. Degradation of NR1H4 mRNA transcripts
can be explained by perfect complementary interference of the
miR-192-3p seed sequence at the two in silico-predicted bind-
ing positions of the NR1H4-3=UTR. The 5= strand of miR-192
also appeared to repress FXR gene expression in vitro, albeit
through a different mechanism. Transfections with the corre-
sponding antagomirs support our findings with both mimics in
our model cell lines.
According to the miRBase database, about 80 different
human miRNA precursors can yield two abundant mature
miRNAs, i.e., the 5= strand (miR-#-5p) and 3= strand (miR-#-
3p) with different seed sequences and mRNAs as binding
targets. There is increasing evidence for interplay between the
5= and 3= strands of the same precursor molecule targeting the
same group of genes, thereby reinforcing a certain phenotype
(10), which can be supported by our data.
Hsa-miR-192 has been shown to play a crucial role in the
pathogenesis of colon carcinoma, the third most common
cancer in Western countries (6). Because of its cancer stage-
dependent decline in expression, miR-192 has been suggested
to be a potential biomarker to predict metastasis in colon
H
sa
-m
iR
-1
92
-3
p
FXRα2(+)
6 
 7
  8
  9
  1
0 
11
4.5               5.0               5.5               6.0               6.5               7.0
01987
color code of variable hsa-miR-192-3p
Fig. 5. Correlation between FXR and miR-192
expression in colonic adenocarcinoma-derived
tissue samples from 27 patients by linear re-
gression analysis. A significant inverse associ-
ation was detected for miR-192-3p and the
NR1H4 mRNA transcript coding for
FXR2() (coefficient 
 	1.57/P 

0.0259).
BA
DC
Caco-2
re
la
tiv
e 
A
la
m
ar
 B
lu
e 
re
du
ct
io
n
48h 72h 96h
0.0
0.5
1.0
1.5
2.0
100nM NC siRNA
100nM FXR siRNA
Huh-7
re
la
tiv
e 
A
la
m
ar
 B
lu
e 
re
du
ct
io
n
48h 72h 96h
0.0
0.5
1.0
1.5
2.0
100nM NC siRNA
100nM FXR siRNA
*
**
Caco-2
re
la
tiv
e 
A
la
m
ar
 B
lu
e 
re
du
ct
io
n
48h 72h 96h
0.0
0.5
1.0
1.5
2.0
100nM NC mimic
100nM miR-192-3p mimic
100nM miR-192-5p mimic
**
re
la
tiv
e 
A
la
m
ar
 B
lu
e 
re
du
ct
io
n
48h 72h 96h
0.0
0.5
1.0
1.5
2.0
100nM NC mimic
100nM miR-192-3p mimic
100nM miR-192-5p mimic
***
*
Huh-7
Fig. 6. Impact of miR-192-5p and -3p (A and
C) or FXR siRNA (B and D) on proliferation
of Huh-7 and Caco-2 cells by alamarBlue
assay. The 48-h values of each condition
were used for normalization. Experiments
were repeated 4 times. ***P  0.001, **P 
0.01, *P  0.05.
G1049MIR-192 SUPPRESSES THE EXPRESSION OF FXR
AJP-Gastrointest Liver Physiol • doi:10.1152/ajpgi.00297.2015 • www.ajpgi.org
carcinoma patients (9). Our findings regarding the inverse
association of FXR and miR-192* expression in colonic cancer
patients suggest that this miRNA-dependent mechanism of
FXR regulation could play an important role in carcinogenesis.
We additionally showed that miR-192 can suppress expression
of the bile acid and anticancer drug transporter OATP1B3 and
the bile acid transporter OST/ in a FXR-dependent manner.
It remains unclear whether restoration of miR-192 expres-
sion and the consequently diminished expression of FXR target
genes would be beneficial for cancer patients, especially con-
sidering that miR-192 has been shown to possibly act as an
oncogenic miRNA by downregulation of Smad interacting
protein 1 in other inflammation-related cancers (21, 26, 35).
Therefore, it can be speculated that diminished expression of
the transport protein OST/OST, a heterodimer-forming bile
acid transporter important for the excretion of bile acids from
hepatocytes and enterocytes, may be a mechanism of intracel-
lular bile acid accumulation promoting inflammation and/or
cancer development in certain cases.
By performing cell proliferation and invasion assays, we
were able to confirm the previously described suppressive role
of miR-192 in liver and colon cancer progression. We observed
a miR-192-associated antiproliferative effect in Huh-7 cells
that is stronger than in Caco-2 cells, where no noteworthy
effects of the 3= strand arm could be seen on FXR protein
levels. Furthermore, knockdown of FXR did not show any
influence on Caco-2 cell proliferation. These observations
support the hypothesis that the antiproliferative effect of miR-
192-3p may be to some extent FXR-dependent. Future studies
have to elucidate to what extent the miR-192/FXR interplay
supports or inhibits tumor pathogenesis. Our results are in line
with reports showing that enhanced FXR expression and the
associated altered expression of FXR-regulated drug-uptake
transporters is related to chemoresistance in cancer patients.
Treatment of the colorectal adenocarcinoma cell line LS174T
with cisplatin leads to a cisplatin-resistant phenotype that is
accompanied by a 350-fold increase in FXR expression (22).
Furthermore, increased expression of OATP1B3 has been
suggested to confer antiapoptotic resistance to paclitaxel by
altering p53-dependent pathways (18).
It may be of value to confirm the detected association
between miR-192 and FXR expression in larger cohorts. We
cannot exclude the contribution of other miRs or epigenetic
factors to FXR regulation. However, a further step would be to
systematically test all in silico-predicted miRs for effects on
the NR1H4-3=UTR.
In conclusion, miR-192-5p and -3p negatively regulate the
expression of FXR in a synergistic manner, thereby signifi-
cantly decreasing the expression of FXR target genes OST/
and OATP1B3. We show a new miR-dependent mechanism of
FXR regulation, which could affect the expression of FXR
target genes and plays a role in the pathogenesis of liver and
colon cancers and their response to anticancer therapies.
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SUPPLEMENTARY FIGURES 
 
 
 
 
Suppl. Figure 1: MicroRNA-192-3p potentially impacts intracellular bile acid homeostasis in Huh-7 cells. 
MicroRNA-192-3p mimic significantly suppressed the mRNA expression of FXR key target genes, which are 
important in the hepatic, anticholestatic compensatory response. The observed miR-dependent suppressive effect 
on the expression of the bile acid transporters BSEP, MRP2, MDR3, OSTα/ß and on the expression of the 
nuclear receptor SHP occurred secondary to the reduced expression of the transcriptional activator FXR 
(confirmed by simultaneous FXR knockdown and miRNA transfection: 100 nM siRNA, miRNA or negative 
control for 48 or 72 h). mRNA levels relative to β-actin were determined by real-time PCR. The miR mimic 
negative control (NC) was used for normalization. 24 h after transfection, cells were treated with 50 µM CDCA 
for 24 h and 48 h, respectively, to activate FXR. Experiments were repeated three times and one sample t-test 
was used for statistical analysis. ** p < 0.01; * p < 0.05; ns, not significant. 
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Suppl. Figure 2: Taurocholate (TCA) transport is influenced by miR-192-3p transfection in Huh-7 cells. 
To study the functional relevance of the observed miR-192-dependent suppressive effect on BSEP expression 
(Suppl. Fig. 1), intracellular TCA concentrations were measured 72 h after miRNA transfection, 2 h after TCA 
incubation and 30 min after bromsulphthalein (BSP) treatment. BSP is a potent inhibitor of the hepatic 
basolateral bile acid transport by repressing OATP and NTCP activities. As NTCP is not expressed in Huh-7 
cells (data not shown), the BSP-dependent effect observed in this experiment can be attributed to OATP 
inhibition. Due to the moderate miR-192-dependent decrease of intracellular TCA levels (20.5%) in BSP-treated 
cells, we conclude that other BSEP-independent, miR-192-3p-suppressed bile acid transporters are involved in 
TCA transport. As miR-192 did not influence the expression of OATP1B1 and as BSEP expression is overall 
low in Huh-7 cells (data not shown), OATP1B3 is probably the predominant TCA transporter in this cell line. To 
activate FXR, 24 h after transfection, cells were additionally treated with 50 µM CDCA for 48 h. The 
experiment was run in duplicates and the miR mimic negative control (NC) w/o BSP was used for normalization. 
ns, not significant.  
Suppl. Method to Figure 2: 72 h after miRNA transfection, cells were incubated for 2 h with 10 µM TCA (cold 
TCA mixed 3:1 with [3H]-TCA (15.4 Ci per mmol, Perkin-Elmer)) and half of the conditions additionally with 
10 µM BSP for 30 min. After four washing steps, cells were lysed with 1% Triton and 150 ul of the lysate were 
measured together with 4 ml Ultima-GoldTM szintillation reagent (Perkin-Elmer) using the TriCarb Liquid 
Szintillation Analyzer (Packard). Count per minutes (cpm)-values were adjusted to the relative protein 
concentrations.  
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Suppl. Figure 3: miR-192-3p and -5p significantly decrease the viability of Huh-7 cells in a FXR-
independent manner. Cell viability was measured 48 h after transfection using Alamar Blue assay. No 
alterations in cell viability were observed after cell treatment with 100 nM FXR siRNA for 48 h (data not 
shown). The miR mimic negative control (NC) was used for normalization. Experiments were repeated three 
times and one sample t-test was used for statistical analysis. * p < 0.05. 
 
 
 
 
 
 
Suppl. Figure 4: FXR-independent effects of miR-192-3p on cyclin D1 and c-jun expressions in Huh-7 
cells. This experiment was performed to study the effect of the miR-192/FXR interplay on target genes known to 
play a crucial role in cell cycle regulation. 72 h after transfection, miR-192-3p significantly induced mRNA 
expression of cyclin D1 and c-jun, but, in a FXR-independent manner. A significant increased expression of 
cyclin D1 and c-jun was also observed after cell transfection of miR-192-5p for 48 h (data not shown). Enhanced 
cyclin D1 and c-jun expressions are both important signs for endogenous cell cycle activation and subsequent 
apoptosis or cell proliferation, dependent on concomitant stimuli. 24 h after transfection, cells were treated with 
50 µM CDCA for 48 h to activate FXR. mRNA levels relative to β-actin were determined by real-time PCR. The 
miR mimic negative control (NC) was used for normalization. Experiments were repeated three times and one 
sample t-test was used for statistical analysis. ** p < 0.01; * p < 0.05; ns, not significant. 
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Abstract 
Aims. OATP1B3 mediates the uptake of endogenous and xenobiotic compounds from portal 
venous blood into the liver. Substrates of OATP1B3 include anti-cancer agents and other 
drugs. The high inter-individual variability in OATP1B3 expression, which is thought to 
impact on drug safety and efficacy, cannot be explained by genetic polymorphisms alone. In 
the current study, we investigated the extent to which microRNAs regulate the expression of 
OATP1B3 (SLCO1B3 gene).  
Main Methods. 21 miRNAs, predicted in silico to putatively bind to SLCO1B3, were tested 
for their regulatory effect on gene expression in luciferase gene reporter assays co-
transfecting them with SLCO1B3 3′-UTR subcloned into pmirGLO luciferase vector. 
Mutations were inserted into the consensus sequences for miR-509-3p or miR-656-3p that 
showed the strongest effect on luciferase activity. SLCO1B3 mRNA and protein were 
measured by real-time PCR and western blot analysis in Huh-7 cell extracts treated with miR-
509-3p, miR-509-5p and miR-656 mimics. Correlation between SLCO1B3 mRNA and miR-
509-3p, miR-509-5p and miR-656 expression was analyzed in human intrahepatic 
cholangiocarcinoma samples using Pearson’s and Spearman’s correlation analyses.  
Key findings. Luciferase activity was site-specifically and significantly decreased in co-
transfection experiments with miR-509-3p or miR-656 mimics. MiR-509 and miR-656-3p 
mimics caused decreased levels of SLCO1B3 mRNA in Huh-7 cells, leading to significantly 
suppressed levels of OATP1B3 protein compared with mock transfected cells. In human 
cholangiocarcinoma, expression of SLCO1B3 mRNA was inversely correlated with miR-509-
5p (p< 0.05).  
Conclusions. In summary, we show that the microRNAs miR-509 and miR-656 regulate 
OATP1B3 expression in vitro and in vivo.  
 
Introduction 
The hepatic transporter organic anion-transporting polypeptide 1B3 (OATP1B3) mediates the 
uptake of many endogenous and exogenous compounds from portal venous blood into the 
liver. OATP1B3 and its close family member OATP1B1 share 80% sequence homology and 
show a partly overlapping substrate spectrum. Important substrates of the OATP family 
comprise bile salts and hormones as well as drugs such as statins, antidiabetics, and several 
anti-cancer drugs including tyrosine kinase inhibitors (i.a. sorafenib), platinum drugs, 
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paclitaxel or SN-38, the active metabolite of irinotecan [1-5]. Several genetic polymorphisms 
in SLCO1B1 have been described, which appear to predispose to altered pharmacokinetics 
and an elevated risk for adverse drug reactions [6-8]. 
Genetic variants of SLCO1B3 (the gene encoding OATP1B3) have also been detected and 
studied, but the relevance of these polymorphisms for drug safety and efficacy has not yet 
been clearly established [9]. A total deficiency of OATP1B1 and OATP1B3, induced by loss 
of function mutations, leads to Rotor Syndrome, a benign accumulation of bilirubin 
glucuronide in the blood associated with jaundice [10]. OATP1B3 displays a high variance in 
hepatic protein expression that varies between 4.9 and 30 fmol/μg protein (range of mean 
expression 1.1 to 6.5 fmol/μg protein) [11]. Several studies have shown that high variance of 
OATP1B3 expression in healthy liver tissue and in hepatocellular carcinoma contributes to 
the variability in measured plasma levels of drugs such as atorvastatin or the liver-specific 
contrast agent gadoxetic acid [12,13]. Teft and colleagues reported that the progression-free 
survival of colorectal carcinoma under irinotecan therapy correlated significantly with the 
expression of OATP1B3 in tumor tissue, underlining the importance of OATP1B3 expression 
for the response to cancer therapy [14].    
The exact molecular mechanisms regulating OATP1B3 expression have not been well 
studied. Imai et al. demonstrated in different cancer cell lines that OATP1B3 expression is 
partly driven by methylation patterns in near proximity to the transcription start site [15]. 
MicroRNAs (miRNAs, miRs) are small molecules of approximately 20 bp that bind to the 3′ 
untranslated regions (UTRs) of target genes and thus inhibit mRNA translation or even lead to 
mRNA degradation. Several drug transporters and drug metabolizing enzymes are regulated 
by miRNAs. CYP3A4, the activity of which shows little modulation due to genetic 
polymorphisms, is regulated by miR-27b and miR-298 [16]. The hepatic export pump MRP2 
appears to be regulated by miR-379, which modulates the expression of this transport protein 
in a rifampicin-dependent manner [17]. No study has yet addressed the extent to which 
OATP1B3 expression is directly regulated by miRNAs. Investigating this regulatory 
mechanism may help explain the observed inter-individual and tissue-dependent variability of 
OATP1B3 expression, and may widen our current understanding of the safety and efficacy of 
therapy with OATP1B3 substrates.  
In this study, we investigated to what extent miRNAs can modulate the hepatic expression of 
OATP1B3. We focused on miRNAs miR-509 and miR-656 (which we predicted in silico as 
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binding to OATP1B3) and studied their impact on OATP1B3 expression in Huh-7 cells and in 
array data of human cholangiocarcinoma samples. 
 
Materials and Methods 
 
Cell culture. Human hepatoma derived Huh-7 cells (American Type Culture Collection, 
Molsheim, France) were cultured in RPMI 1640 medium supplemented with 10% fetal bovine 
serum (Sigma-Aldrich, St. Louis, MO, USA), 100 U/ml penicillin and 100 µg/ml 
streptomycin (Invitrogen, Carlsbad, CA, USA ). Cells were kept at 37°C in an atmosphere 
containing 5% CO2. 
 
In silico prediction of putative miRNA binding sites in SLCO1B3. Putative binding sites 
for miRNAs within the 3′ UTR of SLCO1B3 mRNA were predicted using the bioinformatics 
tools TargetScan (http://www.targetscan.org/), miRANDA (http://www.microrna.org) and 
MicroCosm (http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/). Based on the 
prediction of putative binding to SLCO1B3, initially, 21 miRNAs were selected for a further 
analysis in luciferase gene reporter assays. MiRNAs were tested in gene reporter assays, if a 
binding was predicted with at least two different bioinformatics tools. Additionally, miRNA-
509 (predicted with MicroCosm) was included in subsequent investigations as well due to its 
putative role in liver associated malignant diseases. 
 
Cloning of reporter gene constructs and mutagenesis reactions. To confirm the impact of 
miRNAs on gene expression, luciferase gene reporter assays were performed. The 3′ UTR of 
SLCO1B3 was subcloned into pmirGLO vector (Promega, Fitchburg, WI, USA) using primers 
listed in Table 1 and the restriction enzymes NheI and XbaI (Thermo Scientific, Waltham, 
MA, USA). Recognition sites for the restriction enzymes are underlined in Table 1. The 
pmirGLO reporter vector carries both the firefly and Renilla luciferase reporter genes, which 
allows a direct normalization of the obtained luciferase results without any additional 
transfection of a second reporter vector.   
MiRNAs miR-509-3p and miR-656-3p were detected to significantly downregulate luciferase 
gene reporter activity, To further test the functional relevance of the predicted binding sites 
for these two miRNAs (Fig. 1), the consensus sequences detected in silico were artificially 
mutated using mutagenesis primers (Table 1) and the QuikChange II XL Site-Directed 
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Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) according to the 
manufacturer’s protocol. The mutations were confirmed by DNA sequencing (Microsynth, 
Balgach, Switzerland). Inserted mutations are marked in bold and are underlined in Table 1.  
 
Table 1: Primers used for subcloning and mutagenesis reactions. 
Primer name Direction Sequence Enzyme/miRNA  Application 
1B3_3UTR_FW2 Forward 5′-aggctagccattgcattgattcattaagatg   NheI Subcloning of 
SLCO1B3 3′-end 
into pmirGlo 
1B3_3UTR_RV2 Reverse 5′-agtctagaatttctgaaaaatatacaacttaac XbaI Subcloning of 
SLCO1B3 3′-end 
into pmirGlo 
hsa-miR-509-3p_F Forward 5′-attccaacattctttccgttctgcgcagcgatggataagtctatg miR-509-3p Mutagenesis 
hsa-miR-509-3p_R Reverse 5′-catagacttatccatcgctgcgcagaacggaaagaatgttggaat miR-509-3p Mutagenesis 
hsa-miR-656_F Forward 5′-ccaaaatctggcctgggtgtttccgacaatatatattttcatgtt miR-656-3p Mutagenesis 
hsa-miR-656_R Reverse 5′-aacatgaaaatatatattgtcggaaacacccaggccagattttgg miR-656-3p Mutagenesis 
 
Luciferase gene reporter assays. Luciferase gene reporter assays were performed by 
cotransfecting wild type and artificially mutated constructs into Huh-7 cells. Cells were 
seeded into 48-well plates at a density of 1.6×105 cells/ml per well. 24 h later, cells were 
transfected with 25 nM hsa-mirVANA® mimics to miRNAs or Negative Control #1 miRNA 
mimic (Life Technologies, Carlsbad, CA, USA) together with 100 ng of wild type, mutated or 
empty pmirGLO reporter construct using Lipofectamine® 2000 (Invitrogen, Carlsbad, CA, 
USA) and Opti-MEM I medium (Invitrogen). The activities of firefly and Renilla luciferase 
were measured 48 h after cotransfection using the Dual-Luciferase® Reporter 1000 Assay 
System (Promega, Fitchburg, WI, USA) according to the manufacturer’s protocol. Analysis 
was performed using the GloMax® Multi Detection System (Promega). Each luciferase gene 
reporter assay using wild type and mutated target clones was performed at least in triplicate.  
 
Transient transfections of miR-509-3p and miR-656-3p and real-time PCR. Based on the 
results obtained in luciferase gene reporter assays and in mRNA/miRNA correlation analyses 
of intrahepatic cholangiocarcinoma (ICC) tissue samples (described below), we further 
studied, to what extent miR-509-3p, miR-509-5p and miR-656-3p influence the endogenous 
expression of OATP1B3. Huh-7 cells were transiently transfected with the respective miRNA 
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mimics and SLCO1B3 mRNA levels were determined by real-time reverse transcription 
polymerase chain reaction (RT-PCR). Cells were seeded into 12-well plates at a density of 
8×104 cells/ml and 24 h later transfected with 100 nM hsa-mirVANA® miR-509-3p, miR-
509-5p, miR-656-3p or Negative Control #1 using Lipofectamine® RNAiMax (Invitrogen). 
Cells were harvested after 48 h and 72 h for the extraction of total mRNA using Trizol® 
reagent (Life Technologies) and after 72 h for the extraction of protein using RIPA buffer (50 
mM Tris HCl pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate (all from Sigma-
Aldrich), 1 mM EDTA (Pharmacia Biotech, Uppsala, Sweden), 0.1% SDS (Sigma-Aldrich), 
10% glycerol (Sigma-Aldrich), made up to 1000 ml with ddH20)). Three independent 
experiments were performed. 
For the performance of RT-PCR, 1.5 µg RNA was transcribed into cDNA using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems Waltham, MA, USA). For 
SLCO1B3 mRNA expression analysis, 2 µl of 1:5 diluted cDNA samples and 8 μl of 
SLCO1B3-specific RT-PCR Universal Fast Master Mix were mixed together (TaqMan® Gene 
Expression Assays, Life-Technologies). β-actin (ACTB) mRNA was measured as an internal 
control and used to normalize the RT-PCR results. All measurements were performed in 
triplicate. 
 
Western blot analysis. Huh-7 cell-derived protein extract (5 and 8 µg) was diluted 1:5 in 
loading buffer, denatured and loaded on an 8% SDS-polyacrylamide gel. The separated 
samples were subsequently electroblotted on polyvinylidene fluoride membranes, which were 
blocked for 1 h in 5% (wt/vol) non-fat milk/PBS-Tween 20 (0.1% (vol/vol) Tween 20 in PBS; 
PBS-T) blocking solution. Anti-OATP1B3 serum or anti-β-actin antibody (Abcam, 
Cambridge, UK) was then added and membranes were incubated for 16 h or 1 h, respectively, 
at 4°C. Membranes were washed three times with PBS-T and once with blocking solution, 
and subsequently incubated with a horseradish peroxidase-conjugated secondary antibody 
(goat-anti-rabbit, Thermo Scientific) for 1 h at room temperature. After a second round of 
four washing steps, the bands were visualized and quantified using SuperSignal® West Femto 
Maximum Sensitivity Substrate (Thermo Scientific) and the Fusion FX luminescence detector 
system (Vilber Lourmat, Marne-La-Valle, France). The measured intensities of β-actin bands 
were used to normalize the results for OATP1B3 expression. The experiments were repeated 
three times using three different batches of Huh-7 cells.  
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MessengerRNA/miRNA correlation analyses in cholangiocarcinoma probes. To 
investigate the impact of miR-509 and miR-656 on the expression of SLCO1B3 in vivo, 
Pearson’s and Spearman’s correlation analyses were performed between the expression of 
these miRNAs and SLCO1B3 in human intrahepatic cholangiocarcinoma samples (E-GEOD-
32958, ArrayExpress database (https://www.ebi.ac.uk/arrayexpress/). A panel comprising 20 
cholangiocarcinoma (CCA) samples, i.e. 14 intrahepatic cholangiocarcinoma (ICC) and 6 
combined hepatocellular and cholangiocarcinoma (CHC) samples was investigated with 
regard to these correlations. Expression data were obtained using the Affymetrix Human Exon 
1.0 ST Array (Affymetrix, mRNA determination) and the Nanostring nCounter Human 
microRNA Expression platform (miRNA determination) [18].   
 
Statistical analyses. One sample t-tests were performed to compare the effects of miRNA 
mimics on luciferase gene reporter activity and on endogenous mRNA and protein expression 
of OATP1B3. Results are shown as average values (+/-) standard deviation (SD). In these 
analyses, as well as in the Pearson’s correlation and Spearman’s Rho analyses, p-values ≤0.05 
were considered to be statistically significant. Statistical analyses were performed using R 
((http://www.r-project.org/, version 2.15.2) and GraphPad Prism (GraphPad Software, La 
Jolla, CA, USA; www.graphpad.com, version 5.04). 
 
 
Results 
 
MiR-509-3p and miR-656-3p decrease OATP1B3 mRNA and protein by binding to 
consensus sequences within the 3′ UTR of SLCO1B3. A bioinformatic investigation of the 
3′ UTR of SLCO1B3 with three different bioinformatic tools resulted in the prediction of 
putative binding sites for 21 different miRNAs including miR-509-3p and miR-656-3p (Fig. 
1). Cotransfection experiments in Huh-7 cells revealed strongest downregulations of 
luciferase activity with miR-509-3p mimic and miR-656-3p mimic, leading to a decrease in 
luciferase activity of 85% and 49%, respectively. Subsequent luciferase gene reporter 
experiments focusing on these two miRNAs showed a reconstitution of luciferase activity 
when using pmirGLO-constructs carrying artificially mutated binding sites for miR-509-3p 
and miR-656-3p mimics in cotransfection experiments (Fig. 2). 
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Figure 1: In silico predicted binding sites for miRNA-509-3p and miRNA-656-3p within the 3′ UTR of 
SLCO1B3 mRNA. Predictions were performed using the bioinformatics tools MicroCosm (miR-509-3p) and 
miRANDA (miR-656-3p, microRNA.org).  
 
 
 
Figure 2: Relative reporter gene activities measured in Huh-7 cells 48 h after cotransfection of a 
SLCO1B3-3′ UTR carrying pmirGLO vector and miRNA-509-3p (A) or miRNA-656-3p (B). 
Cotransfections were performed with pmirGLO-wild type clones or pmirGLO-constructs carrying the putative 
binding sites for the respective miRNAs in mutated form. Reporter gene activities measured in mock transfected 
cells were defined as 1. Reporter gene activities were compared with miRNA-mock-transfected cells. 
Measurements were repeated in triplicate. The figure shows the average result of three independent experiments. 
*p < 0.05; **p < 0.01; ns, not significant. 
 
 
MiR-509-3p, miR-509-5p and miR-656-3p significantly downregulate SLCO1B3 mRNA 
in Huh-7 cells. To investigate to what extent miR-509 and miR-656 inhibit OATP1B3 
expression at the mRNA level, i.e., by degrading the SLCO1B3 mRNA, Huh-7 cells were 
transfected with mimics to the miRNA molecules miR-509-5p, miR-509-3p, miR-656-3p or 
negative control. The impact of miR-509-5p on OATP1B3 mRNA and protein expression was 
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investigated here as well, based on significant results in correlation analyses obtained in ICC 
as described below. MessengerRNA amounts of OATP1B3 were determined 48 and 72 hours 
later. As shown in Figure 3A to C, all three miRNA mimics (i.e., miR-509-3p, miR-509-5p 
and miR-656-3p) decreased SLCO1B3 mRNA levels. SLCO1B3 mRNA was significantly 
decreased after 48 h by 41% (miR-656-3p), 54% (miR-509-3p) and 61% (miR-509-5p). 
Compared to miR-656-3p the effect of miRNA-509 on SLCO1B3 mRNA expression was 
even more pronounced as reflected by a strong and significant downregulatory effect of 74% 
(miR-509-3p) and 61% (miR-509-5p), respectively, observed after 72h.  
 
 
Figure 3: Effect of miR-509-3p (A), miR-509-5p (B) and miR-656-3p (C) on the endogenous expression of 
SLCO1B3 mRNA in Huh-7 cells. Huh-7 cells were transfected with the respective miRNA mimics or negative 
control. Cells were harvested after 48 and 72 hours. SLCO1B3 mRNA expression levels were determined by RT-
PCR and normalized to β-actin (ACTB). A significant downregulation of SLCO1B3 mRNA was seen for all three 
miRNAs after 48 h and for the miR-509 molecules after 72 h. Expression levels measured in the mock-
transfected cells were defined as 1. Significance outcomes in the figure describe the pairwise comparison to 
mock transfected cells. The figure shows the average result of three independent experiments. *p < 0.05; ns, not 
significant. 
 
OATP1B3 protein expression is significantly reduced in Huh-7 cells upon treatment 
with miR-509 and miR-656-3p. To investigate to what extent miR-509 and miR-656 
influence OATP1B3 protein expression, Huh-7 cells were transfected with the respective 
mimics to miR-509-5p, miR-509-3p, and miR-656-3p and protein levels of OATP1B3 were 
determined by western blot analysis. As shown in Figure 4A to C, miR-509-3p, miR-509-5p 
and miR-656-3p also decreased OATP1B3 protein expression by 49%, 23%, and 50%, 
respectively, in Huh-7 cells (as shown by the quantification data at the bottom of the figure).  
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Figure 4: MiRNAs 509-3p (A), 509-5p (B) and 656-3p (C) suppress OATP1B3 protein expression levels in 
Huh-7 cells. Cells were transfected with mimics corresponding to the three miRNA molecules or miRNA 
negative control. Cells were harvested 72 h later and protein was extracted. Western blot analyses show the 
expression level of OATP1B3 in comparison to β-actin and in response to the miRNA transfections performed. 
Band intensities were quantified and are shown at the bottom of the figure. Blots show a representative result of 
three independent experiments performed, and the quantification is an average of three independent blots. **p < 
0.01; *p < 0.05. 
 
 
Expression of miRNA-509-5p inversely correlates with the expression of OATP1B3 in 
intrahepatic cholangiocarcinoma. To investigate to which extent the effects of miR-509 and 
miR-656 on OATP1B3 expression observed in vitro can be confirmed in vivo, a panel of 20 
CCA samples, i.e., 14 ICC and 6 combined CHC samples, as well as 2 non-tumor samples 
was investigated with regard to the correlation between SLCO1B3 mRNA expression and the 
expression of miR-509 and miR-656. Expression data were obtained from the dataset E-
GEOD-32958 that contains the mRNA and miRNA profile in cholangiocarcinoma [18]. Using 
the ArrayExpress Archive of functional genomics data obtained in ICC, significant inverse 
correlations were observed for OATP1B3 and miR-509-5p, which were not seen for miR-509-
3p and miR-656-3p (Fig. 5A to C). This further supports our findings in Huh-7 cells that miR-
509-5p exerts an inhibitory effect on OATP1B3 expression. 
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Figure 5: A significant inverse correlation was observed for miR-509-5p and OATP1B3 in Pearson’s 
correlation analyses performed in 14 intrahepatic cholangiocarcinoma samples (E-GEOD-32958, p=0.048, 
coefficient −0.54). These results were confirmed in Spearman’s rho analyses (p=0.046), when taking a non-
normal distribution of OATP1B3, as tested according to Shapiro-Wilk, into consideration.   
 
 
Discussion 
This study investigates to what extent miRNAs modulate the expression of OATP1B3. We 
show that miR-509 and miR-656-3p significantly suppress OATP1B3 expression at both the 
mRNA and protein level. Our findings provide a mechanism for the inter-individual 
variability in OATP1B3 expression that has been repeatedly observed in different disease and 
tissue types.  
The observation that miR-509-5p, miR-509-3p and miR-656-3p suppress OATP1B3 
expression at the mRNA and protein levels suggests that these miRNAs both inhibit and 
degrade SLCO1B3 mRNA. The in silico analysis of the SLCO1B3-3′ UTR revealed putative 
binding sites for miR-509-3p and miR-656-3p and luciferase gene reporter assays showed that 
these two miRNAs appear to bind to the predicted binding sites. The OATP1B3 expression 
data obtained by RT-PCR and western blot analysis in Huh-7 cells suggest that OATP1B3 is 
also suppressed by miR-509-5p. This is further supported by correlation analyses performed 
in a panel of intrahepatic cholangiocarcinoma samples, in which miR-509-5p expression was 
significantly inversely correlated with the expression of OATP1B3. As this correlation was 
distinctly observed in ICC and not in mixed samples composed of ICC and HCC, it can be 
speculated that the miR-509-5p/OATP1B3 interaction plays a considerable role in ICC.  
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The impact of miR-509-5p on OATP1B3 expression could have consequences for the 
therapeutic efficacy of anti-cancer drugs. As shown both in vitro and in vivo in mice, the level 
of OATP1B3 expression is a determinant of the uptake of platinum drugs used, for example, 
for the treatment of hepatocellular or cholangiocarcinoma [3]. The effect of miR-509-5p on 
OATP1B3 expression could, therefore, affect the distribution and accumulation of these drugs 
in cancer cells. Although in vitro effects on OATP1B3 expression comparable with those of 
miR-509-5p were observed for both miR-509-3p and 656-3p, no inverse correlations between 
these two miRNAs and OATP1B3 expression were seen in ICC or CHC, suggesting a weaker 
effect of these miRNAs on OATP1B3 expression in intrahepatic cholangiocarcinoma. Sekyia 
et al. claimed that ICC is mainly generated by biliary lineage cells derived from hepatocytes, 
rather than cholangiocytes [19]. ICC and HCC may therefore share the same cellular origin of 
hepatic stem cells [18]. But, as shown by our data, the epigenetic miRNA-dependent 
regulatory network seems to differ in both liver cancers. It would be interesting to study the 
miR-509/miR-656/OATP1B3 interplay in a larger cohort of HCC samples.  
MiRNA-509 has repeatedly been reported to be involved in regulatory processes that control 
cell migration and cell growth in different forms of cancer. Both miR-509-3p and miR-509-5p 
are thought to be tumor suppressors in renal cell carcinoma and have been shown to suppress 
the development of brain metastases in breast cancer [20-22]. A suppressive effect of miR-
509-5p and miR-509-3p on tumor growth has also been observed in hepatoma and HeLa cell 
lines [23,24]. Ren et al. revealed that miR-509-5p joins the MDM2/p53 feedback loop in 
hepatoma cell lines and suggested tumor-suppressive effects of miR-509 [23]. These data 
confirm an important role for miR-509 in epigenetic regulation, particularly in tumorous 
tissues.  
MicroRNA-656 belongs to a cluster of miRNAs that is decreased in different forms of cancer, 
including glioblastoma multiforme, renal clear cell carcinoma and invasive breast carcinoma 
[25]. Consistent with these results, Yin and colleagues observed a downregulation of this 
miRNA cluster in HCC, which they hypothesized to be mediated by hepatocyte nuclear factor 
4 alpha (HNF4ɑ) [26]. In line with the observation that OATP1B3 appears to be highly 
expressed in extrahepatic tumor entities such as breast cancer, colon cancer, lung or bladder 
cancer, miR-656 seem to have a stronger impact on extrahepatic, cancerous OATP1B3 
expression [27]. In HCC, OATP1B3 expression is decreased in tumorous as compared to non-
tumorous samples [28], which, however, still does not exclude a relevant fine-tuning effect of 
miR-656 on OATP1B3 gene regulation in this type of cancer.  
63 | CHAPTER 3 
 
 
 
In summary, we show that the miRNAs miR-509 and miR-656 regulate OATP1B3 expression 
both in a hepatocyte-derived cell line and at the level of gene expression in human 
intrahepatic cholangiocarcinoma. These findings contribute to our understanding of the high 
inter-individual differences in OATP1B3 protein expression observed in normal liver and 
different tumor entities.  
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V. GENERAL DISCUSSION AND OUTLOOK 
In this work we elucidate how miRNAs play a crucial role within the signaling pathways 
modulated by BAs. We demonstrate a bidirectional interaction between FXR, FXR target 
genes and miRNAs with physiological and pathophysiological consequences for the human 
digestive tract. These findings support the hypothesis that miRNAs are promising drug targets 
and agents for the therapy of diseases affecting the liver or intestine. However, as miRNAs 
are only small molecules within a large and complex epigenetic regulatory network, the risk 
for miRNA-associated off-target effects should not be neglected. 
 
1. The BA-FXR axis interferes with the endogenous miRNA network 
In Chapter 1 we showed that BAs influence the expression pattern of genes and miRNAs 
important in bile acid homeostasis, lipid and drug metabolism. As CDCA is the most potent 
endogenous ligand and activator of FXR, in comparison to other endogenously expressed 
BAs, we chose CDCA in a concentration within physiological range for study performance. 
Lew et al. showed that within the concentration of 50 μM CDCA the most potent FXR 
transactivation is achieved [1]. Additionally, CDCA is an appropriate model substance for 
drugs in development showing a CDCA-similar structure (e.g. the FXR agonist INT-747). 
The link between BAs and their FXR-dependent influence on lipid metabolism or cell cycle 
regulation can be confirmed by our in vitro study. As an example, we will focus here on the 
well described interplay between FXR and its overall suppressive effect on miR-34a 
expression [2], which we could verify by our data. We observed that miR-34a is the p53-
regulated miRNA influenced by the BA-FXR axis in hepatocytes. In contrast, miR-192 or 
miR-509 expressions are not CDCA-dependently changed. This BA-FXR/miR-34a interplay 
may be an explanation for the anti-apoptotic FXR effects observed in several liver diseases. 
Looking more into study detail, the miRNA-associated fine-tuning effects on the expression 
of target genes can be elucidated. The BA detoxifying and drug metabolizing enzyme 
CYP3A4 has been shown to be indirectly miRNA-dependently regulated over RXRα, as 
RXRα is directly targeted by miR-34a [3]. Both, miR-34a and CYP3A4 expressions were 
significantly negatively regulated by the BA-FXR axis in human hepatocytes [4]. The strong 
inverse correlation between miR-34a and CYP3A4, however, reveals that miRNAs are still 
able to fine-tune the expression of their target genes, even when the expressions of all 
interaction partners are treatment- or disease-dependently downregulated. 
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2. FXR and its target genes are directly and indirectly regulated by miRs 
Until now, no epigenetic, miRNA-associated, regulatory mechanism of FXR expression has 
been shown to have potential implications for altered BA homeostasis and cell apoptosis. 
Disturbed signaling pathways of cell cycle regulation are described to play a crucial role in 
several diseases of the human digestive tract such as BA-induced liver injuries, NAFLD or 
cancer. As miR-192 and FXR are well known to be key players in apoptotic processes, their 
interaction may be important in the pathomechanism of several hepatic or digestive diseases. 
To increase the mechanistic value of the miR-192/FXR interplay, transfection experiments 
shown in Chapter 2 were further confirmed in HepG2 and HT-29 cells (data not shown). As 
aforementioned, even if the expressions of miR-192 and FXR seem to be simultaneously 
decreased in colon cancer [5,6], a fine-tuning miR-192-dependent regulatory effect on FXR 
expression is still possible in this type of cancer. This hypothesis is in line with the results 
obtained in the correlation analysis between miR-192-3p and FXR expression, where we 
analyzed 27 adenocarcinoma tissue samples. As the role of FXR in cell growth and 
cancerogenesis is still controversially discussed, future in vivo studies have to elucidate to 
what extent the miR-192/FXR interplay supports or inhibits tumor pathogenesis. In Chapter 2 
we could confirm that miR-192-3p significantly decreases proliferation of Huh-7 and Caco-2 
cells. However, only in the hepatoma cell line a partial FXR-dependent effect was observed. 
Further studies verified that miR-192 FXR-independently impairs cell viability of Huh-7 cells 
and regulates the expression of the cell cycle regulators cyclin D1 and c-jun (Chapter 2, 
Suppl. Fig. 3 and 4). These findings are in line with the described pro-apoptotic role of miR-
192 [7]. The study of Roy et al. confirmed that miR-192 is involved in the regulation of cell 
death during oxidative stress-induced liver injury in mice [8]. We therefore conclude that the 
miR-192-dependent anti-proliferative effects on Huh-7 and Caco-2 cells may have their origin 
in the cell cycle regulatory role of miR-192 and to a certain extent in the interplay of miR-192 
and FXR. These miR-192-associated effects are underlined by in vivo data, showing e.g. that 
miR-192 expression levels are increased in NAFLD, in which cell death counts as a disease 
key feature [9]. In contrast, expression of miR-192 was significantly suppressed in HCC 
tissue compared with non-tumorous tissue [10]. We therefore speculate that cancer cells may 
decrease the endogenous miR-192 expression due to its negative effects on cell viability. 
Comparable effects and the same expression behavior in NAFLD and HCC were observed for 
miR-34a, another p53-regulated miRNA [11,12]. 
In this work we further showed that miR-192 exhibits potentially disturbing effects on BA 
homeostasis. MiR-192-3p significantly downregulated the expression of FXR target genes 
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secondary to reduced FXR expression in Huh-7 cells - genes known to play a crucial role in 
the intracellular, anticholestatic compensatory response of hepatocytes: BSEP, MRP2, MDR3, 
OSTα/β and SHP (Chapter 2, Suppl. Fig. 1). However, intracellular [3H]-TCA levels did not 
significantly change upon transfection of Huh-7 cells with miR-192-3p (Chapter 2, Suppl. 
Fig. 2). The results obtained from the bromsulphthalein-treated cell conditions confirm that 
TCA is not a specific marker for BSEP-controlled BA efflux in Huh-7 cells. Due to the study 
of Kullak-Ublick et al. and to our data, we assume that TCA uptake into Huh-7 cells is mainly 
OATP-mediated [13]. As NTCP is not expressed in Huh-7 cells and OATP1B3 expression 
was the only hepatic OATP transporter influenced by miR-192, we conclude that Huh-7 cells 
are not the optimal model cell line to study the miR-192-dependent effect on BA homeostasis. 
OATP1B3 seems to be the predominant BA transporter being responsible for the TCA 
equilibrium in this hepatoma cell line. But as the relevance of OATP1B3-dependent BA 
uptake into hepatocytes is believed to be negligible in vivo, an important role of the miR-
192/FXR interaction on BA homeostasis has still to be further investigated in future studies.  
We showed that miR-192-3p and -5p regulate the expression of FXR and FXR target genes 
and we revealed pathological implications of this interplay on hepatic and digestive diseases 
such as intrahepatic cholestasis, NAFLD or cancer – 1) via alteration of BA homeostasis, 2) 
via disturbed direct effects of FXR or 3) via FXR-independent effects of miR-192 – due to its 
potential impact on cell cycle regulation, inflammatory processes or lipid metabolism. The 
proliferation experiments and Suppl. Figures 3-4 in Chapter 2 illustrate that the miR-192-
associated effects on cell cycle regulation and cell viability are to some part FXR-dependent – 
via e.g. disturbance of BA homeostasis – and to another part FXR-independent – via e.g. the 
impact on JNK/c-jun pathway. As cyclin D1 and the JNK/c-jun pathway are also playing a 
role in enhanced cell proliferation, the impact of miR-192 on these pathways have to be 
investigated in better fitting transfection models. From this cell cycle-regulatory impact, 
undesirable pleiotropic effects of potential miR-192 therapeutics cannot be excluded  
Besides hepatocytes, miR-192 and FXR are also expressed in cholangiocytes, whereas FXR 
expression e.g. in hepatic stellate cells is absent, which makes a direct role of the 
miRNA/FXR interplay on the hepatic fibrotic response less likely [14,15].  
Shifts in microRNA expression can lead to altered drug pharmacokinetics by deregulated 
expression of drug metabolizing enzymes and transporters. In this work we showed that 
OATP1B3 expression is directly influenced by miR-509-3p, -5p and miR-656. Additionally, 
miR-192-3p and -5p suppress OATP1B3 expression in a FXR-dependent manner. We 
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illustrate that a specific gene is directly and indirectly regulated by five miRNAs in its 
expression. Considering the enormous amount of >140 in silico predicted miRNAs binding to 
the 3’UTR of OATP1B3 (www.microrna.org), we probably just show here a small section of 
the whole endogenous, complex miRNA network being involved in the regulation of 
OATP1B3 expression. As OATP1B3 is a drug transporter important for the cellular uptake of 
several standard chemotherapeutics (e.g. sorafenib against HCC; platin derivates or irinotecan 
against colorectal cancer), shifts in miRNA expression as observed e.g. during cancerogenesis 
can consequently lead to an altered efficacy of these drugs [16-18]. This fact particularly has 
to be considered in current drug development, where miRNAs are discussed as potential drug 
targets against different types of cancer, used in monotherapy or in combination with current 
standard chemotherapeutics. As shown by the OATP1B3 example, the “multi-to-one” 
relationship of several miRNAs regulating the expression of a specific gene further elucidates 
a potential drug resistance mechanism. By changing the endogenous expression pattern of a 
miRNA with a mimic or inhibitor, the expression levels of the target gene can still remain 
unchanged due to a subsequent changed expression of other target gene-regulating miRNAs 
[19]. Coming back to the OATP transporter, the role of OATP1B3 in chemoresistance is 
controversially discussed. On the one hand, decreased uptake of chemotherapeutics due to 
suppressed OATP1B3 expression may lead to a diminished sensitivity to cancer therapy. On 
the other hand, frequently observed OATP1B3 overexpression in e.g. colorectal 
adenocarcinoma has been associated with an apoptotic resistance to oxaliplatin in a p53-
dependent manner. Lee et al. observed that OATP1B3 overexpression decreases the 
transcriptional activity of p53 [20]. Based on our findings we suggest that the p53-regulated, 
apoptotic miRNAs miR-509 and miR-192 are missing pieces in a regulatory feedback loop 
consisting of p53/miR-509/miR-192 and OATP1B3. This feedback loop may confer apoptotic 
resistance to OATP1B3-transported, but possibly also to non-OATP1B3-transported 
chemotherapeutics.  
 
3. Are miRNAs future drug targets for liver and digestive diseases? 
MicroRNAs were detected around 1990, but only after 2000 they gained more interest, as 
they were found to be highly conserved throughout mammalian species and to be able to 
regulate important biological processes within different organisms [19]. As aforementioned, 
miRNAs are currently discussed to be high-value drug targets and agents. Former defined 
“undruggable” proteins can potentially be modified by miRNA-dependent gene regulation. 
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The ability of miRNAs, to simultaneously regulate a large set of target genes, is discussed to 
be beneficial in multipathway diseases such as cancer, where several oncogenes can be 
miRNA-dependently suppressed at the same time.  
MiRNA mimics and inhibitors are synthesized as exonuclease-resistant, anti-sense agents, 
which implicates several pharmacological problems [21]. Firstly, these molecules exhibit 
limited tissue distribution due to low lipophilicity and rapid excretion into urine. The delivery 
problem is tried to be solved by advanced formulations (nanoparticles, liposome- or antibody-
based methods) or chemical modifications [22]. One serious, often discussed problem 
regarding miRNA therapeutics includes their pleiotropic effects. A single miRNA can 
regulate up to hundreds of genes, whereas a single gene can be regulated simultaneously or 
sequentially by multiple miRNAs - facts we have tried to highlight by this work. Several 
possible mechanisms of miRNA-dependent regulation of protein expression (translational 
repression vs. mRNA degradation; binding to the 3’UTR of a target gene vs. binding to the 
5’UTR or coding region of a target gene) or the additional epigenetic regulation of the 
miRNAs itself (methylation of their promoter, histone modification) even further increase the 
complexity of the miRNA-mediated gene regulatory network in vivo [19]. Due to these facts it 
is not surprising that in vitro miRNA studies are not satisfactory reproducible and that the 
number of subsequent clinical trials is limited [23]. MiRNA-associated off-target effects can 
only be revealed by an intensified study in good animal models and by performing human 
long-term studies. Price et al. further mention the miRNA-associated problem of tissue 
specificity, because miRNAs seem to play distinct roles in different tissues and in different 
cell types within the same organ [19]. In case of the p53-regulated miRNAs miR-192 or miR-
34a as possible miRNA therapeutic agents, targeted drug delivery to the diseased tissue would 
have to be achieved. A drug delivery into healthy tissue should be avoided as both p53-
regulated miRNAs have the potential to disturb the BA-FXR axis and/or decrease cell 
viability. In general, a miRNA inhibitor is probably more specific, as it exerts only activities, 
where the targeted miRNA is endogenously expressed. A miRNA mimic can distribute 
throughout the whole body, unless a targeted delivery can be guaranteed. A targeted delivery 
formulation to the diseased cell type has to include the attachment of folic acid, peptides or 
antibodies interacting specifically with antigens on the cell surface of e.g. tumors [22,24]. One 
example for a tissue-specific miRNA is miR-122, which is predominantly expressed in the 
liver. MiR-122 binds to the 5’UTR of the hepatitis C virus genome and promotes virus 
replication in the liver [25]. Miravirsen, a locked nucleic acid antagomir against miR-122, is 
currently tested in clinical phase II for hepatitis C treatment [22]. In contrast, miR-192 and 
71 | DISCUSSION 
 
 
 
miR-34a are expressed in various types of tissue, increasing the risk for undesired adverse 
drug reactions if used as a compound. MRX34, a liposome-formulated miR-34 mimic has 
become the first miRNA replacement therapy to reach phase I clinical trials as a potential 
cancer therapeutic agent [26]. As a known cell cycle regulator and a miRNA, which 
simultaneously regulates several oncogenes, miR-34 induced a complete HCC regression in 
mouse models [22,23]. First results obtained in clinical phase I trial confirmed partial 
responses to MRX34 treatment in HCC patients (www.mirnarx.com). MRX34 tumor uptake 
is claimed to be enhanced by the particular chemical composition of the liposome. The 
liposome may turn from an anionic into a cationic state in liver tumor microenvironment, 
which has a lower pH as compared to healthy tissue [26].  
As aforementioned, our work illustrates the problem of “unknown” miRNA-associated off-
target effects due to complexity of the endogenous human miRNA network. We showed that 
one miRNA directly regulates FXR expression, whereas disturbances of the BA-FXR axis 
may lead to significant changes in the expression of >80 miRNAs within hepatocytes. 
Considering the fact that one miRNA targets up to hundreds of genes, (long-term) drug safety 
of a potential miRNA therapeutic that influences FXR expression, is difficult to estimate. This 
concern can further be expanded to the safety of CDCA-analogical drugs, such as the FXR 
agonist INT-747. 
 
4. Methodological problems and limitations 
In Chapter 1, CDCA was used for FXR transactivation. Therewith, FXR-independent BA 
effects cannot be actively excluded in data interpretation. A next step would include a FXR-
miRNA interaction study by using a more specific FXR activator such as INT-747.  
To prove the miR-192-dependent regulation of FXR expression, standard methods were used 
and optimized (Chapter 2). Thereby, transient miRNA transfections only guarantee a miRNA-
dependent target gene regulation for 72-96 h. As we observed miRNA-dependent effects on 
FXR and OATP1B3 protein levels after 72 h in Huh-7 cells, stable miRNA transfections 
would be more appropriate to study the functional relevance of the miRNA/mRNA interplay 
(e.g. for transport assays). Furthermore, the 5’ strand of the miR-192 precursor only showed 
non-significant suppressing effects on FXR protein levels in Huh-7 cells, which might be 
technically biased by the overall higher, endogenous miR-192-5p expression. The “missing” 
effects of the miR-192-5p/FXR interplay on proliferation of Huh-7 cells for example, have to 
be interpreted with caution. Therefore, the effects of the miR-192/FXR interplay on the 
regulation of BA homeostasis were only investigated for the 3’ strand. Moreover, some of the 
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cell transfections with miRNA inhibitors revealed partially reproducibility problems, 
dependent on the cell line used (Caco-2 cells were partly problematic) and dependent on cell 
passage number (higher passage number were more problematic). MicroRNA inhibitors are 
small, chemically modified single-stranded RNA molecules designed to complementary bind 
to the target miRNA. We could show that also miR-192-5p, the complementary strand of 
miR-192-3p, influences FXR expression, which may explain the partial variability of the 
obtained results as the inhibitors in some outlying experiments also downregulated FXR 
expression. Given the fact that transfection experiments including miRNA mimics were ab 
initio good reproducible, further experiments were performed with mimics only.  
As aforementioned, in vitro studies cannot reflect the whole human endogenous miRNA 
network involved in gene regulation. Furthermore, the effect of signaling pathways involving 
several different human organs (e.g. immune response, hormone signaling, BA homeostasis) 
is not optimally mimicked in cell line studies. Therefore, this work just illustrates a selection 
of signals induced by miRNA/mRNA interplay with implications for the pathophysiology of 
liver and digestive diseases. The early performance of in vivo studies is necessary in miRNA 
therapeutic research: 1) for a better understanding of the miRNA(s)/mRNA(s) interplay and 
its influence on signaling pathways throughout the human body, 2) to decrease the linked risk 
of miRNA-dependent off-target effects and 3) to guarantee tissue-/cell-specific drug delivery.  
 
5. Outlook 
We conclude that a bidirectional interaction between FXR and miRNAs is of importance for 
physiological and pathological effects on the human digestive system. This work illustrates 
the complexity of the whole human miRNA network by three examples: 1) the significant 
impact of the BA-FXR axis activation on > 80 miRNAs in hepatocytes, 2) the influence of 
miR-192 on the expression of FXR and other target genes in a “one-to-multi”-relationship, 
and 3) the miRNA-dependent regulation of OATP1B3 expression in a “multi-to-one” 
relationship. Therewith, the limitations of in vitro studies as well as the necessity for early 
performance of in vivo studies have been elucidated.  
Regarding the miR-192/FXR interplay, more initial in vitro research investigating potential 
effects on the maintenance of BA homeostasis would be essential. Therefore, primary human 
hepatocytes or HepaRG cells, a hepatic cell line known to express BSEP and NTCP, would be 
the cell models of choice for further transport experiments. Additionally, stable viral-based 
miR-192 transfections should be performed, to guarantee long-term miRNA expression within 
cells. As we saw a miR-192-dependent effect on FXR protein levels not until 72 h, long-term 
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effects of this interplay on intracellular BA homeostasis and/or cell proliferation after more 
than 96 h would be interesting to investigate. Furthermore, the apoptotic role of the miR-
192/FXR interplay should be examined including appropriate programmed cell death-
experiments such as mitochondrial ATP production, transmembrane potentials, cytochrome c 
release or caspase activation. A further step would be to test the miR-192 mimic effects in a 
good mouse model, including also FXR knockout mice. But as the miRNA network is not 
congruent between mice and humans, early performance of human studies is inevitable. As 
miR-192 is described to be an apoptotic, p53-regulated miRNA, a targeted miR-192 
therapeutic would have to be designed, which affects diseased tissue only. As miR-34a and 
miR-192 show a similar miRNA expression behavior within multiple liver diseases, the 
effects on FXR expression and disease progression after co-transfection of both miRNAs 
would be interesting. Possibly, a liver-specific miR-192/miR-34a inhibitor would be a 
potential treatment for NAFLD, which may strongly re-establish FXR expression and 
transactivation, may maintain a non-toxic, physiological BA homeostasis and therefore may 
decrease apoptosis and progression of the disease.  
Potential off-target effects always have to be considered in future miRNA therapeutic 
development. But probably, not all the possible miRNA-dependent mechanisms of protein 
expression regulation have been detected so far. Buchan et al. described for example, a 
miRNA-dependent repressing and enhancing role of mRNA translation dependent on cell 
cycle state and concomitant RNA binding proteins [27]. These two faces of miRNAs open 
new questions, which join the pool of questions already existing in the complex miRNA 
universe. Or as Sevignani et al. described the miRNA network: “MicroRNAs are small stars 
in the genome galaxy with many surprises still in store” [28]. 
 
 
 
 
 
 
 
 
74 | DISCUSSION 
 
 
 
REFERENCES 
1) Lew JL, Zhao A, Yu J, Huang L, De Pedro N, Peláez F, et al. The farnesoid X receptor controls gene 
expression in a ligand- and promoter-selective fashion. The Journal of biological chemistry. 
2004;279:8856-61. 
2) Lee J, Kemper JK. Controlling SIRT1 expression by microRNAs in health and metabolic disease. Aging 
(Albany NY). 2010;2:527-34. 
3) Oda Y, Nakajima M, Tsuneyama K, Takamiya M, Aoki Y, Fukami T, et al. Retinoid X receptor α in 
human liver is regulated by miR-34a. Biochemistry & pharmacology. 2014;90:179-87. 
4) Zhang S, Pan X, Jeong H. GW4064, an agonist of farnesoid X receptor, represses CYP3A4 expression in 
human hepatocytes by inducing small heterodimer partner expression. Drug metabolism and disposition: 
the biological fate of chemicals. 2015;43:743-8. 
5) Geng L, Chaudhuri A, Talmon G, Wisecarver JL, Are C, Brattain M, et al. MicroRNA-192 suppresses 
liver metastasis of colon cancer. Oncogene. 2014;33:5332-40. 
6) Lax S, Schauer G, Prein K, Kapitan M, Silbert D, Berghold A, et al. Expression of the nuclear bile acid 
receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa 
independent from site and may be associated with adverse prognosis. International journal of cancer. 
2012;130: 2232-9. 
7) Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, et al. Downregulation of p53-
inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple 
myeloma development. Cancer Cell. 2010;18:367-81. 
8) Roy S, Benz F, Alder J, Bantel H, Janssen J, Vucur M, et al. Down-regulation of miR-192-5p protects 
from oxidative-stress induced-acute liver injury. Clinical science (London, England : 1979). 2016. 
9) Pirola CJ, Fernández Gianotti T, Castaño GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma 
M, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding 
RNAs to liver histology and disease pathogenesis. Gut. 2015;64:800-12. 
10) Lian J, Jing Y, Dong Q, Huan L, Chen D, Bao C, et al. miR-192, a prognostic indicator, targets the 
SLC39A6/SNAIL pathway to reduce tumor metastasis in human hepatocellular carcinoma. Oncotarget. 
2016;7:2672-83.  
11) Castro RE, Ferreira DM, Afonso MB, Borralho PM, Machado MV, Cortez-Pinto H, et al. miR-
34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in 
human non-alcoholic fatty liver disease. Journal of hepatology. 2013 Jan;58:119-25. 
12) Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, et al. miR-34a inhibits migration and invasion by down-
regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer letters. 2009;275:44-53. 
13) Kullak-Ublick GA, Beuers U, Paumgartner G. Molecular and functional characterization of bile acid 
transport in human hepatoblastoma HepG2 cells. Hepatology. 1996;23:1053-60. 
14) Baghdasaryan A, Claudel T, Gumhold J, Silbert D, Adorini L, Roda A, et al. Dual farnesoid X 
receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy 
model by promoting biliary HCO⁻₃ output. Hepatology. 2011;54:1303-12. 
75 | DISCUSSION 
 
 
 
15) Silakit R, Loilome W, Yongvanit P, Chusorn P, Techasen A, Boonmars T, et al. Circulating miR-192 in 
liver fluke-associated cholangiocarcinoma patients: a prospective prognostic indicator. Journal of hepato-
biliary-pancreatic sciences. 2014;21:864-72. 
16) Lancaster CS, Sprowl JA, Walker AL, Hu S, Gibson AA, Sparreboom A. Modulation of OATP1B-type 
transporter function alters cellular uptake and disposition of platinum chemotherapeutics. Molecular 
cancer therapeutics. 2013;12:1537-44. 
17) Yamaguchi H, Kobayashi M, Okada M, Takeuchi T, Unno M, Abe T, et al. Rapid screening of 
antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent 
probes. Cancer letters. 2008;260:163-9. 
18) Zimmerman EI, Hu S, Roberts JL, Gibson AA, Orwick SJ, Li L, et al. Contribution of OATP1B1 and 
OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clinical cancer research : an official 
journal of the American Association for Cancer Research. 2013;19:1458-66. 
19) Price C, Chen J MicroRNAs in Cancer Biology and Therapy: Current Status and Perspectives. Genes & 
Diseases. 2014;1:53-63. 
20) Lee W, Belkhiri A, Lockhart AC, Merchant N, Glaeser H, Harris EI, et al. Overexpression of OATP1B3 
confers apoptotic resistance in colon cancer. Cancer Research. 2008;68:10315-23. 
21) Schmidt MF. Drug target miRNAs: chances and challenges. Trends in biotechnology. 2014;32:578-85. 
22) Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nature 
reviews. Drug discovery. 2014;13:622-38. 
23) Otsuka M, Kishikawa T, Yoshikawa T, Yamagami M, Ohno M, Takata A, et al. MicroRNAs and liver 
disease. Journal of human genetics. 2016. 
24) Yu B, Zhao X, Lee LJ, Lee RJ. Targeted delivery systems for oligonucleotide therapeutics. American 
Association of Pharmaceutical Scientists journal. 2009;11:195-203. 
25) Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA 
abundance by a liver-specific MicroRNA. Science. 2005;309:1577-81. 
26) Agostini M, Knight RA. miR-34: from bench to bedside. Oncotarget. 2014;5:872-81. 
27) Buchan JR, Parker R. Molecular biology. The two faces of miRNA. Science. 2007;318:1877-8. 
28) Sevignani C, Calin GA, Siracusa LD, Croce CM. Mammalian microRNAs: a small world for fine-tuning 
gene expression. Mammalian genome : official journal of the International Mammalian Genome Society. 
2006;17:189-202. 
 
 
 
 
 
76 | C V 
 
 
 
VI. CURRICULUM VITAE 
 
 
KRATTINGER, Regina          
* 01.05.1985       Habsburgstrasse 49 
Zürich ZH/Düdingen FR     8400 Winterthur, Switzerland 
Nationality: Swiss      078 608 41 45 
        regina.krattinger@bluewin.ch 
 
 
EDUCATION 
 
03/2013 - 09/2016 
PhD research studies in the group of Prof. Dr. G. A. Kullak-Ublick (Department of Clinical 
Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland) 
 
Topic: Bidirectional interaction between farnesoid X receptor and microRNAs 
 
Doctoral program: Integrative Molecular Medicine (imMed), Zurich Center for Integrative Human Physiology 
(ZIHP), University of Zurich 
 
 
2007 - 2009 
Master’s degree and federal state exam in Pharmacy 
(University of Basel, Basel, Switzerland) 
 
Master thesis in the group of Prof. Dr. Alex N. Eberle (Laboratory of Endocrinology, 
Department of Biomedicine, University Hospital Basel, Basel, Switzerland) 
 
Topic: 3T3 cell mitochondria targeting with analogues of the tetrapeptide DALDA – Study of mitochondrial 
function, membrane potential and apoptosis 
 
 
2004 - 2007 
Bachelor’s degree in Pharmaceutical Sciences 
(University of Basel, Basel, Switzerland) 
 
 
2000 - 2004 
Eidg. Matura 
(Kantonsschule Heerbrugg, St. Gallen, Switzerland; focus Spanish) 
 
 
PROFESSIONAL EXPERIENCE 
 
11/2010 - 10/2016 
Research assistant and pharmacist at the Department of Clinical Pharmacology and 
Toxicology, University Hospital Zurich, Zurich, Switzerland 
 
 
 
77 | C V 
 
 
 
05/2011 - 02/2013 
Pharmacist at TopPharm Apotheke Witikon, Zurich, Switzerland 
 
 
10/2009 - 09/2010 
Pharmacist at Montana-Apotheke Arosa, Grisons, Switzerland 
 
 
09/2008 - 06/2009 
Assistant pharmacist at Hard-Apotheke Birsfelden, Basel, Switzerland 
 
 
TEACHING EXPERIENCE 
 
2013 - 2015 
 
Teaching assistant at practical courses for 1st and 2nd year medical students (Institute of 
Physiology, University of Zurich); Topics: Membrane transport, Heart-ECG, Respiration, 
Vision 
Teaching assistant at practical courses „Xenobiotic metabolism“ for bachelor students in 
medicine and master students in biomedicine (Department of Clinical Pharmacology and 
Toxicology, University Hospital Zurich) 
 
AWARDS 
 
2015  Hartmann Müller Foundation Travel Grant 
 
2013 3rd Best poster award, Annual Meeting of Swiss Society of General Internal 
Medicine (SSGIM) 
 
 
ORAL PRESENTATIONS 
 
01/2016 Wednesday morning seminar of the internal medicine clinics, University 
Hospital Zurich, Zurich, Switzerland 
 
07/2015 Pichlschloss Transport Meeting, Styria, Austria 
 
 
POSTER PRESENTATIONS 
 
11/2015 The Liver Meeting 2015 - American Association of the Study of Liver 
Diseases (AASLD), San Francisco, CA, USA 
 
08/2015 11th Symposium of the Zurich Center for Integrative Human Physiology, 
Zurich, Switzerland  
 
 
78 | C V 
 
 
 
06/2015 13th Congress of the European Association for Clinical Pharmacology and 
Therapeutics (EACPT), Madrid, Spain 
 
06/2015 10th Retreat of the PhD Program imMed, Solothurn, Switzerland 
 
08/2013 The Zurich Pharmacology Pharma Poster Day 2013, Zurich, Switzerland 
 
05/2013 Annual Meeting of Swiss Society of General Internal Medicine (SSGIM), 
Basel, Switzerland 
 
 
PUBLICATIONS 
 
Published 
 
Krattinger R, Boström A, Schiöth HB, Thasler WE, Mwinyi J, Kullak-Ublick GA. microRNA-192 
suppresses the expression of the farnesoid X receptor. Am J Physiol Gastrointest Liver Physiol. 2016 
Jun 1;310(11):G1044-51.  
 
Krattinger R, Boström A, Lee SM, Thasler WE, Schiöth HB, Kullak-Ublick GA, Mwinyi J. 
Chenodeoxycholic acid significantly impacts the expression of miRNAs and genes involved in lipid, 
bile acid and drug metabolism in human hepatocytes. Life Sci. 2016 Jul 1;156:47-56. 
 
 
Accepted for Publication - In Press 
 
Niedrig D, Krattinger R, Jödicke A, Gött C, Bucklar G, Russmann S. Development, implementation 
and outcome analysis of semi-automated alerts for metformin dose-adjustment in hospitalized patients 
with renal impairment. Pharmacoepidemiol Drug Saf. 2016. 
 
 
In Preparation 
 
Kullak-Ublick GA, Krattinger R, Claro DaSilva T, Boström A, Dutler N, Schiöth HB, Mwinyi J. The 
organic anion transporting polypeptide OATP1B3 is regulated by microRNA-509 and microRNA-656. 
 
Boström A, Mwinyi J, Krattinger R, Kullak-Ublick GA, Cunningham JB, Schiöth HB (prelim. list). 
Genome-wide methylation study identifies and confirms hypomethylation of hsa-mir-4646 in 
depression. 
 
 
Textbooks 
 
Siepmann T, Kirch W, Kullak-Ublick GA. Arzneimitteltherapie, 2nd Edition. Thieme, Stuttgart. 2016. 
– Müller EA, Krattinger R: Chapter “Gastrointestinale Erkrankungen“. – In Press 
 
Camm AJ, Lüscher TF, Maurer G, Serruys PW, The ESC Textbook of Cardiovascular Medicine, 3rd 
Edition. Kullak-Ublick GA, Krattinger R: Chapter “Gastrointestinal diseases - Intestinal absorption 
and drug levels”. – In Preparation  
79 | ACKNOWLEDGEMENT 
 
 
 
VII. ACKNOWLEDGEMENT 
First of all, I would like to thank everyone who accompanied me during my PhD years. It was 
a very interesting time, in which I gained a lot of professional knowledge and met a lot of new 
friends. It was a time, which will remain unforgettable. 
I am very grateful to my supervisor Prof. Gerd Kullak for his support during the last six years 
that I have worked in his department. Thank you for giving me the chance to gain professional 
experience in the entire field of basic and clinical pharmacology. 
I would also like to thank Dr. Jessica Mwinyi for her support, supervision and teaching. 
Jessica, I am very happy that you came along with me through my PhD. I always appreciated 
your valuable inputs, our productive discussions and our friendship a lot!  
I would further like to thank my PhD committee members Prof. Olivier Devuyst, Prof. 
François Verrey, Prof. Christoph Handschin and Dr. Remi Terranova for their interest, inputs 
and support throughout the duration of my PhD. Many thanks also to Adrian Boström for all 
the statistical analyses, which he contributed to my publications. 
I am very grateful to all past and present members of the Clinical Pharmacology team. I am 
very happy to call myself a part of this great team during the last six years. My first thanks go 
to the lab in Schlieren: Prof. Bruno Stieger, Dr. Michele Visentin, Dr. Gai Zhibo, Dr. Tatiana 
Claro Da Silva, Carlos Schaffner, Zainab Mahdi, Evelin Krajnc, Christian Hiller, Stephanie 
Bernhard and Moritz Töllke. Many thanks for all your kindness and help. Michele, thank you 
for taking your time to answer all my questions. Tatiana, thank you for your wonderful 
friendship – you always brought sunshine in our lab. Christian and Carlos, many thanks for 
your technical support and detailed explanations. My further thanks go to our Clinical 
Pharmacology team at the hospital, especially Dr. Isabelle Marti, Dr. Stefan Weiler, Dr. 
Natascia Corti, Dr. Alexander Jetter, Dr. Stefan Russmann, Dr. David Niedrig and Rose 
Bosshard. Thank you for all your medical, pharmacological and pharmacoepidemiological 
teaching and kindness. Rose, thank you for always having an open ear. Isabelle, I will always 
remember your laugh, your sociality and your enthusiasm for medicine. Thank you for being 
such a great friend! I will never forget you for the rest of my life. 
 
I am especially grateful to my husband, my parents, my brothers, my parents-in-law including 
Nani, and my friends. Thank all of you for your support and help during my good and bad 
PhD times. To Roman and to my parents: Thank you for all your love and infectious 
optimism. Nothing in this world can substitute you! Because you are the most important 
persons in my life… 
80 | FINAL THOUGHTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Look up at the stars and not down at your feet. Try to make sense of what you see, and 
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